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“I insist upon the view that 'all is waves'.” 
quoted by Walter Moore in  



















 Erwin Schrodinger had once said “No self is of itself alone”. This work would 
have been impossible without the effort and perseverance of my supervisor Dr. 
Kunchithapadam Swaminathan. I owe a lot to Dr. Swami for providing me with 
excellent guidance and motivation for both the professional and personal aspects of 
this journey. I am thankful to him for patiently tolerating my mistakes and politely 
pointing them out to me and, in the process, moulding me into a better researcher. I 
also want to thank him for keeping his door always open, both literally and 
metaphorically, to listen to my problems and provide solutions. 
 I also express supreme gratitude and thanks to Dr. Eric Xu of Van Andel 
Institute, USA (VAI), for hosting me in his lab and providing with excellent 
infrastructure and guidance. Dr. Xu’s motivation for his work was very infectious and 
an example for me to look up to. Dr. Xu also taught me how to think as a researcher 
and how to ask scientifically relevant questions. Dr. Augen Pioszak taught me a 
number of experimental techniques. He also expertly showed me how to design 
experiments and communicate the results. I want to thank a lot all the wonderful 
people with whom I could spend my most memorable moments during this time, 
especially, Avi and Krishna for very stimulating discussions on all aspects, from 
science to philosophy. I should also thank them for hosting me on innumerable 
lunches and dinners at their homes in Grand Rapids and being my only source of 
delicious home cooked food far away from my own home. Life was made so much 
easier and enjoyable in Grand Rapids by other wonderful friends and colleagues: 




Most of my time was spent in NUS and I am lucky to have had so many 
wonderful friends there. My seniors Dileep and Asha have been very approachable 
and a perpetual source of advice on the scientific as well as professional front. Present 
and former members of SBL5 Rajesh, Jobi, Keith, Cherlyn and Lissa have been very 
helping and I have learned a lot from discussions with them. I also owe a lot to 
present and former members of SBL4 Anupama, Vindhya, Toan, Umar, Fengxia, 
Kanmani, Jikun, Deepthi and many others who have come and gone for creating a 
wonderful and congenial work environment. I want to thank friends Thangavelu, 
Manjeet, Abhilash, Rishi, Vamsi, Karthik and Moorthy who shared with me 
numerous lunches and dinners, experimental reagents, experiences and advise.  
In the end I want to reserve this space for people who were not only my batch 
mates but also happened to be my closest friends during this time Vinod, Kuntal, 
Sunil and Veeru. I would like to thank Vinod for all the good times and also for 
listening to and letting me vent out all my thoughts, worries and frustrations. I want to 
thank Kuntal for all the fun and memorable times in Singapore and US. Sunil for 
teaching me molecular biology right from agarose gel analysis onwards and also for 
all the advise on life and living. Veeru for all the wonderful times and being a 






Table of contents 
iii 
 
TABLE OF CONTENTS 
 
Page 
Acknowledgement         i 
Table of contents         iii 
Summary          vii 
List of abbreviations         viii 
List of figures          ix 
List of tables          xi 
CHAPTER 1. X-RAY CRYSTALLOGRAPHY     1 
1.1 INTRODUCTION        1 
1.2 UNIT-CELL         7 
1.3 POINT GROUP AND SPACE GROUP     8 
1.4 RECIPROCAL LATTICE AND EWALD SPHERE    10 
1.5 STRUCTURE FACTOR       12 
1.5.1 Structure factors as a complex number    13 
1.5.2 Electron density       13 
1.6 METHODS TO SOLVE PHASE PROBLEM    15 
1.6.1 Multiple isomorphous replacement (MIR)    16 
Table of contents 
iv 
 
  1.6.1.1 Patterson Function      18 
 1.6.2 Multiwavelength anomalous dispersion (MAD)   19 
 1.6.3 Molecular replacement (MR)      20 
1.7 REFINEMENT        22 
CHAPTER 2.  PITUITARY ADENYLATE CYCLASE ACTIVATING 
POLYPEPTIDE RECEPTOR 1: A CLASS B G-PROTEIN COUPLED 
RECEPTOR                     24
   
2.1 INTRODUCTION        24 
2.2 THE RECEPTORS        25 
 2.2.1 Classification        25 
  2.2.1.1 Class-A (Rhodopsin-like)     26 
2.2.1.2 Class-B (Secretin receptor-like)    27 
2.2.1.3 Class-C (Glutamate receptor-like)    27 
2.2.1.4 Class D (Adhesion receptor-like)    28 
2.2.1.5 Class E (Frizzled/Taste2 receptor-like)   28 
2.3 TRANDUCERS        29 
2.4 EFFECTORS         30 
2.5 MECHANISM OF SIGNALLING      32 
2.5.1 Ligand binding and receptor activation    32 
2.5.2 Gα activation        34 
Table of contents 
v 
 
2.5.3 Activation of receptors      35 
2.5.4 Signal deactivation       35 
2.6 PITUITARY ADENYLATE CYCLASE ACTIVATING  
POLYPEPTIDE 1 RECEPTOR: CLASS B GPCR               36 
 
 2.6.1 Discovery        36 
2.6.2 Structure of the Pac1R gene      38 
2.6.3. Pharmacology of PACAP:PAC1R interaction: structure of PACAP 40 
CHAPTER 3. MATERIALS AND METHODS     45 
3.1 PROTEIN PRODUCTION        45 
3.2 DSBC PURIFICATION       49 
3.3 CRYSTALLIZATION, DATA COLLECTION AND STRUCTURE 
DETERMINATION        50 
3.4 PEPTIDE BINDING ASSAY      52 
3.5 DOCKING OF PACAP8-27 TO PAC1R-ECD    54 
CHAPTER 4. RESULTS        57 
4.1 PROTEIN PRODUCTION       57 
4.1.1 Disulphide shuffling       59 
4.2 HORMONE BINDING ASSAY      62 
4.3 CRYSTALLIZATION OF PAC1R      65 
Table of contents 
vi 
 
4.4 STRUCTURE OF MBP-PAC1R(25-140)-H6    67 
4.4.1 Crystal Packing       67 
4.4.2 Fold of Pac1R-ECD       70  
4.4.3 Molecular determinants of Pac1R:PACAP interaction  75 
4.4.4  Peptide docking to receptor ECD     76 
CHAPTER 5. DISCUSSION       80 












 Pituitary adenylate cyclase activating polypeptide (PACAP) is a member of 
the PACAP/glucagon family of peptide hormones, which controls many physiological 
functions in the immune, nervous, endocrine, and muscular systems. It activates 
adenylate cyclase by binding to its receptor, PAC1R, a member of class B G-protein 
coupled receptors (GPCR). Crystal structures of a number of Class B GPCR 
extracellular domains (ECD) bound to their respective peptide hormones have 
revealed a consensus mechanism of hormone binding. However, the mechanism of 
how PACAP binds to its receptor remains controversial as an NMR structure of the 
PAC1R ECD/PACAP complex reveals a different topology of the ECD and a distinct 
mode of ligand recognition. Here a 1.9 Å crystal structure of the PAC1R ECD is 
reported, which adopts the same fold as commonly observed for other members of 
Class B GPCR. Binding studies with alanine-scanned peptides and mutated receptor 
ECD support a model that PAC1R uses the same conserved fold of Class B GPCR 
ECD for PACAP binding, thus unifying the consensus mechanism of hormone 
binding for this family of receptors. 
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CHAPTER 1. X-RAY CRYSTALLOGRAPHY 
 
1.1 INTRODUCTION 
Objects in our world exist in a wide array of sizes, ranging from the cosmic scale to 
the atomic and sub-atomic scales. In order to see an object, we, usually, illuminate the object 
and then focus, with the help of a lens, the scattered light onto a detector. Light, or any 
electromagnetic radiation, scatters when it interacts with matter. This interaction, which 
causes scattering, can be of two types: 1) elastic, in which the kinetic energy of the incident 
and the scattered light is same and 2) inelastic, in which the kinetic energy of the scattered 
light is not conserved with respect to the incident light. Elastic scattering can be further 
divided into different types, based on certain properties. The kind of elastic scattering that 
describes the scattering of X-rays by crystals in the bio-molecular crystallography paradigm 
is called as Thomson scattering. Thomson scattering was originally formulated by Joseph 
John Thomson, who won an unshared Noble Prize in 1906 for his ‘theoretical and 
experimental investigation on the conduction of electricity by gases’. It deals with the 
behaviour of electromagnetic radiation scattered by free charged particles. As we will see 
later, X-rays are scattered by the electrons of atoms that make crystal, bringing bio-molecular 
crystallography to the realm of Thomson scattering. While we are able to use the scattering of 
visible light to view most objects in our daily life, it suffers from some fundamental 
limitations that limit its use for protein structure determination.  
There is a lower limit to the size of the detail that can be observed by this method. 
Two points that are separated from each other by a distance smaller than λ/2 (where λ is the 
wavelength of the used incident light) cannot be viewed as separate points. Visible light 
denotes a small range of wavelengths in a wide spectrum of electromagnetic radiation, Fig. 
1.1. 




Figure 1.1. The entire electromagnetic spectrum of light, which comprises of 
a large range of wavelengths. Visible light forms a very small portion within 
it, comprising of wavelengths between 390 to 750 nm. The scale at the bottom 
shows the objects that have comparable dimensions with the wavelengths. 
Adapted from http://ds9.ssl.berkeley.edu/LWS_GEMS/pdfs/em-spectrum.pdf  
 
The human eye can sense wavelengths in a narrow range of 3900-7500 Å. The lower 
limit of the distance between two points which can be measured is called the resolution limit 
(dmin) of observation. This dmin is dependent on two factors: the wavelength of the light used 
and the numerical aperture (NA) of the lens used to focus the scattered light (Eq. 1) 
𝑑𝑚𝑖𝑛 =  λ2 NA 
 NA of the lens in our eyes defines the resolution of objects we are able to separate 
with our naked eyes. In order to peer deeper into the microscopic scale, we artificially extend 
the NA by making use of external lenses. NA of a man-made lens can even be given a 
theoretical value of 1, which then imposes a restriction on dmin to depend solely on the 
wavelength of the light being used. Therefore, the theoretical limit of dmin for visible light is 
100-200 Å. In order to achieve atomic resolution, dmin should be in the range of the van der 
Waals radius of atoms and it is impossible to use visible light for achieving this. Although the 
use of higher frequency radiation was proposed long time back, progress in this direction was 
Eq. 1 
Chapter 1. X-ray crystallography 
3 
 
impaired by the practical limitations of using frequencies in the ultraviolet (UV) range, due to 
its property to rupture chemical bonds. Bio-molecular crystallography, therefore, became 
plausible when Wilhelm Conrad Roentgen reported the discovery of X-rays in 1895. X-rays 
have a wavelength of 0.1-100 Å and are deemed appropriate for atomic resolution. Photons 
with longer wavelengths (such as ultraviolet radiation) do not have the ability to provide the 
desired resolution. On the other side, higher energy radiations (such as gamma rays) have 
practical difficulties in production and, in addition, interact destructively with matter 
producing particle-antiparticle pairs, making them unsuitable for bio-molecular 
crystallography. Therefore, X-rays provide an ideal compromise for determining the structure 
of bio-molecules in their native form at atomic resolution.  
The behaviour of light, when scattered by matter, is easily understood by the 
Huygens-Fresnel principle, which states that every point in an advancing wave-front can be 
assumed to be the source of another wave (Fig. 1.2). Connecting equivalent points from the 
wave of all individual point sources gives back the shape of the original wave-front after 
having advanced to the new position. Blocking this wave-front with an opaque screen having 
a slit gives rise to an interesting behaviour characteristic of all waves. If the slit is much 
larger than the wavelength (Fig. 1.2a) of the incoming wave then the shape of the original 
wave-front can be formed on the other side of the slit. If, on the other hand, the diameter of 
the slit is comparable in size to the wavelength of the incoming wave-front, then the shape of 
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a     b 
 
 
   
Figure 1.2. (a) Every point on an advancing wave-front can be assumed to be 
a point source of another wave. Considering the waves from all the point 
sources gives us back the original wave-front, which has now advanced from 
the original position. Putting an opaque screen in front of the advancing wave-
front would block it, unless there is a slit in the opaque screen. If this slit is 
very large then every point in the portion of the wave-front that manages to 
pass through acts as a point source to give us back the shape of the original 
wave-front. (b) If the slit is reduced in size such that its diameter is equal to 
the wavelength of the incoming radiation then only one point source can pass 
through. This then creates a wave-front that is much different in shape than the 
original wave-front.  
 
Extending from this, if another slit (also comparable in diameter with the wavelength) is 
made adjacent to the first slit then we get two point sources of radiation. The waves from 
these two point sources would then interfere at points of varying phase difference to result in 
a smear of radiation at the detector. The question then is, how to arrange the array of slits 
such that the wavelets from each of the point sources precisely add up at certain points and 













Figure 1.3. The slits, having diameter in the range of the incident light’s 
wavelength, made on an opaque screen act as point sources of radiation. The 
waves from these point sources interfere with each other depending on their 
phase differences. By making the slits at certain regular intervals it is possible 
to make sure that all the wave-fronts from the new point sources add-up at 
certain points called as ‘max’ and nullify at certain points called as ‘min’ to 
give rise to a diffraction pattern (figure adapted from Rupp, 2009). 
 
It is interesting to note that due to the comparable sizes of the van der Waals radius of atoms 
and the wavelength of X-rays, atoms scatter X-rays in a manner analogues to Fig. 1.2b, in 
which each atom acts as a point source of X-ray (albeit the structure factor of the scattered X-
ray varies for different atom types, vide infra, in a manner that it contains the imprint of the 
atom that scattered it). The search for this pattern in which the atoms (or slits from Fig. 1.3) 
have to be arranged in order to give an alternating pattern of maxima and minima that result 
in a diffraction pattern led William Lawrence Bragg and William Henry Bragg to give the 
most fundamental equation of X-ray crystallography, known as Braggs’s law (Eq. 2, Fig. 
1.4).  
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𝑛 𝜆 = 2𝑑 sin 𝜃 
  
 
Figure 1.4. Bragg’s law describes the relationship between the angle of 
incidence and distance between the planes of points to achieve constructive 
and destructive interference that forms a diffraction pattern. 
 
Bragg’s law (Eq. 2) provides a quantitative relationship of the wavelength (λ), the 
angle of the incident radiation (θ) and the distance between the planes of atoms (d), which 
scatter the X-rays, in diffraction (while n= any integer 1,2,3…). Therefore, a precisely 
ordered arrangement of atoms is a pre-requisite for diffraction. This enables us to use 
diffraction images to study the underlying ordered arrangement of atoms, which produce it. 
In other words, crystals are nearly perfect arrangement of atoms in three dimensions. Yevgraf 
Fyodorov, Arthur Schoenflies, William Barlow and others had formulated a classical theory 
of atomic arrangement in crystals, known as the space group theory, even before the 
discovery of X-rays (and their use in crystals). This theory is also applicable to bio-molecular 
crystallography. As would be elaborately discussed later, the arrangement of diffraction spots 
that emanate from the diffraction of X-rays by a crystal is indicative of the arrangement of 
atoms in the crystal, while the intensity and phase of the diffraction spots carry an imprint of 
Eq. 2 
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the identity and location of atoms. This knowledge can be used to build a 3-dimensional 
model of a molecular structure.  
 
1.2. UNIT-CELL  
 When solute molecules arrange in an ordered manner to enter a crystalline state, they 
adopt one among a limited number of orientations. An ordered arrangement entails a fixed 
orientation of each molecule in relation to its neighbours. Therefore, it is possible to 
fractionate a crystal into a minimum volume, which, when repeated multiple times, will 
generate the whole crystal. This minimal building block is defined as the unit-cell. The unit-
cell has three non coplanar lattice vectors a, b and c, with interaxial angles α, β and γ, Fig 1.5.  
 
Figure 1.5. The unit-cell is the translationally repeating building block that 
generates a crystal.  
 
The magnitude of the lattice vectors a, b and c along with the angles α, β and γ are known as 
the unit-cell parameters. Based on the unit-cell parameters (which usually supports 
symmetry, vide infra), every crystal can be divided into one among the following crystal 
systems (Fig. 1.6). Taking this classification a step further and allowing unit-cells to form 
interlaced arrangement (known as unit-cell centering), the 7 crystal systems form 14 Bravais 
lattices (Fig. 1.7), named after the French physicist Auguste Bravais, who first proposed it in 
1845.  
 




Figure 1.6. Based on the unit-cell parameters (which usually support the 
demands of symmetry), all the crystals can be divided into 7 systems. The 
primitive lattice of each crystal system is shown on the rightmost column.  
  
1.3 POINT GROUP AND SPACE GROUP 
 The spatial relations that relate neighbouring motifs are called symmetry operations. 
Crystals follow three classes of symmetry operations known as (1) inversion, (2) reflection 
and (3) translation. The allowable combinations of these crystallographic symmetry 
operations in the primitive unit-cell of the 7 crystal systems are known as the crystallographic 
point groups. 
 




Figure 1.7. The 14 Bravais lattices of crystals.  
 
There are 32 point groups. Expanding these point groups by allowing translations for the 
basic symmetry elements rotation and reflection and including the lattice types will make 230 
possible types of crystallographic packing, known as space groups. Of these 230 space 
groups, many entail the inclusion of enantiomeric motifs. The fact that all proteins are made 
up of only L-amino acids and do not have any enantiomeric D-amino acids restricts the 
ability of natural proteins to crystallize only in 65 chiral space groups (Hahn, 2006), Table. 
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1.4  RECIPROCAL LATTICE AND THE EWALD SPHERE 
Working with crystal geometry and Bragg reflections can be enormously simplified 
for mathematical calculations and illustration of diffraction by using the concept of 
‘reciprocal lattice’. A crystal, or the array of unit-cells, can be reduced to a set of repeating 
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lattice points. The whole 3-dimentional lattice can be sliced using a set of parallel imaginary 
planes in a periodic fashion. The planes are then named as h, k, l, known as Miller indices, 
which are the integral number of parts into which the plane divides each unit-cell parameter 
a, b and c, respectively. Therefore, an infinite set of planes can be made through the real-
space lattice, with each set having a unique value for h, k and l. The distance between two 
adjacent parallel planes is then represented by the vector ‘dhkl’ and is called as the interplanar 
distance. To convert this real space lattice into a reciprocal lattice, a lattice point should be 
drawn from each point in the real-space at a distance of 1/dhkl (represented as d*hkl) and 
normal to the hkl plane. The set of points drawn in this manner form the reciprocal lattice. 
The reciprocal lattice was used by physicist Paul Ewald to give the general geometric 
interpretation of diffraction, known as the Ewald sphere (Fig. 1.8) (Ewald, 1969).  
 
Figure 1.8. The Ewald construction of X-ray diffraction. 
 
If a sphere of radius ‘r’ = 1/λ is drawn and the incident beam of X-rays hits the real space 
plane (hkl) at ‘O’ at an angle ‘θ’ and gets reflected making an equivalent angle COB then AC 
= sinθ/λ. By geometry, AC=BC, therefore, AB=2AC. Now, as shown above 2AC = 2(sinθ/λ). 
According to Bragg’s law 2(sinθ/λ) = 1/dhkl. As described earlier, 1/dhkl is equal to d*hkl. 
Therefore, point ‘B’ can be assumed to be a point in the reciprocal lattice and if it coincides 
with the Ewald sphere then Bragg’s law is satisfied.  
According to the Ewald construction, diffraction from a hkl plane will only occur 
when the corresponding d*hkl lies on the Ewald sphere. Therefore, upon exposing a crystal to 
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X-rays, only a few of the reciprocal lattice points will be sampled. The crystal is, hence, 
rotated so that the reciprocal lattice also rotates and more points intersect with the Ewald 
sphere and be recorded in the detector (Fig. 1.9).  
 
Figure 1.9. In geometric interpretation of a diffraction experiment, a crystal 
can be assumed to be at the centre of the Ewald sphere. The detector is placed 
behind the crystal to record diffraction spots (figure adapted from Rupp, 
2009).  
 
1.5 STRUCTURE FACTOR 
Using Bragg’s law and the Ewald construction it is possible to determine where the 
spot from each hkl plane will get collected on the detector. Once the reciprocal lattice has 
been constructed in this manner, it can be converted to a real space lattice. However, the real 
space lattice obtained in this manner will only be a collection of points forming the unit-cell 
with no information about the molecular contents of the unit-cell. In order to learn about the 
molecular contents of a unit-cell, the contribution of each atom in the crystal towards each 
observed Bragg reflection needs to be calculated. To do this, each observed reflection is 
deconvoluted into the partial contribution of the individual atomic scattering factors (of all 
atoms in the unit-cell) in the direction of the observed reflection. The deconvolution into 
partial contribution of individual scattering factors is done with the aide of the mathematical 
concept of complex numbers.  




1.5.1 Structure factors as a complex number 
Working with scattering factor of waves can be simplified for mathematical 
calculations and diagrammatic interpretation by representing them as complex numbers. A 
complex number can be represented as ‘a + ib’ where ‘a’ is called the ‘real’ component and 
‘ib’ is called the imaginary component, where ‘i’ is √−1. In the complex number system, the 
contribution of the imaginary component lies in an orthogonal direction to the real number. 
The complex number a+ib would then represent ‘a’ units in the x direction (real axis) and b 





Figure 1.10. The complex number system. A wave can be represented by a 
complex number. 
 
Waves can be conveniently represented using this system. The amplitude of a wave 
can be represented by ‘r’ and ‘θ’ can be used to represent the phase angle of the wave, Fig. 
1.10. This ‘a+ib’ representation is called the rectangular form of the wave and can be used to 
calculate the properties of waves using the rules of the complex number mathematics. 
 
1.5.2 Electron density 
Each spot on the detector is the total scattering factor in the direction hkl and is called 
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𝐅ℎ𝑘𝑙 = �𝑓𝑗  𝑒2𝜋𝑖(ℎ𝑥𝑗+𝑘𝑦𝑗+𝑙𝑧𝑗)𝑛
𝑗=1
 
where ‘fj’ represents the atomic scattering factor of atom ‘j’, hkl represent the Miller indices 
of the plane that is forming the Bragg reflection while x, y and z represent the fractional 
coordinates of atom j in the unit-cell. The atomic scattering factor is a close approximation of 
the Gaussian function having its centre at sinθ = 0. The scattering factor decays rapidly with 
increase in the diffraction angle. 
After calculating the contribution of scattering in the direction of each hkl for all the 
atoms, it is now desirable to interpret the electron density at each point within the unit-cell. 
Calculation of the electron density in the unit-cell provides us a picture of the electron cloud 
of each atom, thereby locating the atom in the unit-cell. The problem of obtaining the 
electron density at any point of the unit-cell is a problem of switching from the reciprocal 
space of structure factors to the real space of unit-cell contents. The relationship of the two 
domains is explained by the mathematical formulation of Fourier transformation, developed 
by the French mathematician Jean Baptiste Joseph Fourier. Using the principles of Fourier 
analysis, the calculation of electron density is a reverse Fourier transform of structure factors 
(Eq. 4), where V= volume of the entire unit cell.  
 





The task of visualizing the 3-dimentional structure of a protein is reduced to 
determining the location of each atom in the unit-cell of a protein crystal. As is evident from 
Eqs. 3 and 4, the problem of calculating the location of each atom in the unit-cell depends on 
determining the structure factor of the reflecting planes, where the structure factor of the 
reflecting planes can be calculated by summing up the atomic scattering contribution in the 
particular direction, which in turn depends on the position of the atom in the unit-cell 
Eq. 3 
Eq. 4 
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bringing us back to the original problem. The structure factors of a crystal are determined 
experimentally in a diffraction experiment and the information is fed to the problem loop to 
determine the location of each atom in the unit-cell and visualize the 3-dimentional structure 
of the protein molecule. However, a technological inability limits the complete determination 
of experimental structure factors. This is due to the fact that structure factors are composed of 
amplitude as well as phase angles of the diffraction waves. While the detector is able to 
measure the amplitude of the diffraction spot the information about the phase angle is 
immeasurable. The problem of crystallography, in both small molecular and macromolecular, 
therefore, is reduced to the problem of accurately estimating the phase of X-rays. 
 
1.6 METHODS TO SOLVE THE PHASE PROBLEM 
While it is not possible to experimentally obtain the phase angle for all the spots 
recorded on the detector, it is possible to estimate and derive them indirectly or directly from 
the reflections. The method or strategy chosen for solving the phase problem depends on 
some considerations. However, all methods help to obtain enough initial phase angles to 
enable the formation of interpretable electron density maps. Once an interpretable electron 
density map has been obtained, a partial model of the protein can be built which then needs to 
be refined to optimize selected parameters iteratively. Additional phases are then obtained 
from the partial model to further improve the electron density maps and build more regions of 
the structure. Statistical parameters from the model are analysed at each step of model 
building and refinement to verify conformity with the experimentally obtained data. Iterative 
cycles of model building and refinement, while comparing the conformity with 
experimentally obtained data, therefore, gradually improves the electron density maps to 
yield the final structure. The final structure is, hence, a model whose conformity has 
adequately been refined using the experimental data. 
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1.6.1 Multiple isomorphous replacement (MIR) 
MIR is one of the earliest methods used by bio-molecular crystallographers to obtain 
near accurate phase information for some of the reflections and to enable the generation of 
initial electron density maps. The principle of MIR lies in the fact, as explained earlier, that 
all atoms in the crystal contribute towards each observed reflection. When a few heavy atoms 
(like Au, Pt etc.) are added to the protein crystal then the changes in the reflection intensities 
can be used to obtain initial phases. First it is important to emphasize here that the changes in 
reflections should come only from the added atoms and not due to other perturbations. 
Therefore, it is essential that the additional atoms do not alter the unit-cell dimensions of the 
crystal. In addition, the added atom should be heavy enough that it does not get drowned in 
the contributions from other protein atoms to a reflection and leads to measurable changes in 
the observed reflection intensity.  
Every Fhkl in a heavy atom derivatized crystal should have a different intensity 
compared to the native (underivatized) crystal. In a derivative, the phase angle of a reflection 
is shown to be dominated by the heavy atom(s) and in order to determine the phase angle, the 
location of the heavy atom in the unit-cell need to be determined. The location of the heavy 
atom can be determined using the Patterson function (Patterson, 1934), as explained in the 
next section. Using the location of the heavy atom and using them in Eq. 3, Fhkl can be 
calculated. Let us refer the structure factor of the derivative as FHP, and that from the native 
protein crystal can be called as FP while that from the heavy atom alone (heavy atom sub-
structure) can be referred as FH. As these structure factors are additive, 
𝐅HP = 𝐅H +  𝐅P 
or, 
𝐅P =  𝐅HP −  𝐅H 
Eq. 5 
Eq. 6 
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Fig. 1.11 represents the above equation. From the co-ordinates of the heavy atom and Eq. 3 
FH can be determined. Since, the value of the complex number FH is known, the amplitude 
and phase can be represented as the length and angle, respectively, of the vector FH. In order 
to determine FP, first -FH is drawn from the origin. From the head of the -FH vector, another 
vector FHP can then be drawn. We can measure the amplitude of FHP as it is equal to �IHP, 
but we cannot measure its phase. Therefore, we can represent FHP as a circle of radius |FHP| 
centred on the head of -FH (Fig. 1.11). Then, the phase angle of FP is given by the intersection 
of the two circles. It is evident that we get two phase solutions for FP. In order to obtain a 
unique solution, this process can be repeated again with another heavy atom, which labels at 
a separate position. Drawing the third circle from the head of another vector –FH2, we will get 
two solutions, of which one of them will be nearly identical to one of the two solutions from 
the first heavy atom and using the set of Fps, an electron density map can be computed. 
 
 
Figure 1.11. Pictorial representation of the multiple isomorphous replacement 
method. Note that a single heavy atom derivative gives two phase angles for 
every reflection Fp. Hence, at least two heavy atom derivatives are needed to 
break this phase ambiguity.  
 
 
Chapter 1. X-ray crystallography 
18 
 
1.6.1.1 Patterson Function 
The Patterson function is crucial for determining the sub-structure of heavy atoms and 
is analogous to Eq. 4, which is used to calculate electron density from structure factors, albeit 
with a variation. It is a Fourier series that uses only the amplitude of the structure factors and 
does not use the phase (Eq. 7). As the structure factor amplitudes can be directly derived from 
spot intensities, no additional information is required for calculating a Patterson map.  
𝑃(𝑢, 𝑣,𝑤) =  1V���|𝐅ℎ𝑘𝑙2 | 𝑒−2𝜋𝑖(ℎ𝑢+𝑘𝑣+𝑙𝑤) 
𝑙𝑘ℎ
 
A Patterson map constructed using Eq. 7 produces peaks at the head of vectors drawn 
from every atom to all atoms, including itself, in the unit-cell. The peaks in the Patterson map 
are also referred as Patterson atoms. Therefore, if there are n atoms in a unit-cell, then there 
would be n(n-1) Patterson atoms in the Patterson unit-cell. The enormity of the peaks makes 
interpretation of the Patterson map extremely difficult. However, interpretation can be 
simplified if the Patterson map has been calculated from only a few atoms. Hence, the 
Patterson map of only the heavy atoms is calculated in the MIR method. To calculate the 
Patterson map of the heavy atoms, a difference Patterson function is used. The amplitudes of 
the difference Patterson function are obtained from Eq. 8. 
 (∆𝐅)2 = (|𝐅HP| −  |𝐅P|)2 
 
Now, applying the Patterson function from Eq. 7 the difference Patterson function can be 
given as (where V= unit cell volume), 
 
∆𝑃(𝑢, 𝑣,𝑤) =  1
𝑉
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For example, if there is a heavy atom A in the unit-cell, and if B is its symmetry mate, 
then the Patterson map will have peaks at the head of vectors AB and BA. These two vectors 
are equal in amplitude but opposite in direction. Therefore, if AB is represented by the 
Patterson coordinates u,v,w, then BA will be represented as -u,-v,-w, which shows that the 
Patterson map is always centrosymmetric. In addition a Patterson map has two other 
properties: (1) the lattice type of the Patterson cell is the same as that of the real crystal lattice 
and (2) the space group of the Patterson lattice can be derived from the space group of the 
real space lattice by replacing all the translational symmetry elements by their corresponding 
non-translatory ones and by adding a centre of symmetry.  
It can be shown that the vectors between atoms related by symmetry have one or two 
constant coordinates. Once the Patterson atoms have been obtained for the heavy atoms using 
the difference Patterson function, the real heavy atom positions in the unit-cell can be 
calculated largely by a procedure proposed by Harker, known as Harker sectioning, which 
uses the space group information.  
 
1.6.2 Multiwavelength anomalous dispersion (MAD) 
Phase information can also be extracted by using the property of elements to absorb 
X-rays at a particular wavelength. The absorption of X-rays by atoms drops suddenly close to 
a characteristic wavelength(s), known as the absorption edge(s) of the element. When data is 
collected at the absorption edge, Freidel’s rule does not hold good and Ih,k,l ≠ I-h,-k,-l. Certain 
heavy atoms, selenium and sulphur absorb at wavelengths that can be easily generated in 
today’s synchrotron radiation facilities and can be effectively used in labelling a crystal for 
solving a structure with the MAD method.  
The scattering at the absorption edge is called anomalous scattering and can be 
characterised as, 




𝜆2 =  𝐅HP𝜆1 +  ∆𝐅𝑟 +  ∆𝐅𝑖 
where ΔFr and ΔFi are the real and imaginary components of the scattering contribution. 𝐅HP
𝜆2  
and 𝐅HP
𝜆1  are structure factors of the heavy atom derivatized protein crystal at a wavelength 
where it does and does not show anomalous scattering respectively. Representing Freidel 
pairs with superscripts + and – it can be shown that in the absence of anomalous scattering 
|F|+ = |F|- while αhkl+ = - αhkl-. It can also be shown that in Eq. 10, ∆𝐅𝑟+ and ∆𝐅𝑟− are mirror 
images of each other at the anomalous wavelength. In addition, the imaginary contributions 
are inverted reflections of each other i.e. ∆𝐅𝑖+ is a reflection of ∆𝐅𝑖− with the direction 
reversed. A Patterson function can be used to locate the heavy atoms in the unit-cell and 
obtain the complete values of ∆𝐅𝑟 and ∆𝐅𝑖. Using the laws of vector addition in Eq. 10 and a 
construct analogous to Fig 1.11, two solutions for 𝐅HP
𝜆2  (equivalent to FP in MIR). In order to 
break the phase ambiguity, data from another wavelength is needed. To achieve this, help is 
taken from the fact that the real and imaginary anomalous scattering factors, ∆𝐅𝑟 and ∆𝐅𝑖, 
vary greatly at the absorption edge. Close to the absorption edge ∆𝐅𝑟 reaches a minimum 
value and as it begins to ascend, ∆𝐅𝑖 reaches a maximum value. These two wavelengths, 
therefore, can be used for anomalous behaviour while a wavelength far from the absorption 
edge can be used for non-anomalous behaviour of atoms during diffraction.  
 
1.6.3 Molecular replacement (MR) 
MIR and MAD are powerful techniques to obtain experimental phases for structure 
determination, but both of them suffer from the major drawback of having the necessity to 
label the protein with heavy atoms and requiring more than one dataset. As more and more 
protein structures are being solved, another technique, called Molecular Replacement (MR), 
is gaining importance. MR makes use of the fact that if the structure of a target protein is 
likely to be similar to an already known structure then the phases from the known structure 
Eq. 10 
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will be a close approximation of the actual phases from the target structure. Proteins that 
share high degree of sequence similarity also tend to share significant structural similarity. 
Therefore, the calculated phases from a model structure can be combined with the measured 
intensities of the target protein to obtain interpretable electron density maps. After repeated 
cycles of iterative model building and refinement, the phases of the target structure will 
become more accurate.  
In order to obtain meaningful phases from the phasing model, it is required to orient it  
similar to the target protein’s orientation in the unit-cell. In the absence of the structure of the 
target protein, the correct orientation to choose is unknown. Space group considerations place 
some restrictions on the orientation of the phasing model inside the unit-cell of target protein. 
However, the number of possible orientations are still very large and extremely computer 
intensive for a brute force search. The criteria used for search is that the calculated structure 
factor intensities from the phasing model at a particular location should be similar to the 
observed structure factor intensities from a diffraction experiment. For a brute force approach 
to search for the best orientation, the phasing model needs to be rotated around and translated 
along 3 axes, producing 6 parameters for optimization. Exhaustively trying different values 
for these 6 parameters at random is an extremely computer intensive task as the number of 
possible combinations will be extremely large. However, the task can be made less intensive 
if the rotation and translational searches are performed separately (Rossmann and Blow, 
1962). In order to enable separate searches for the rotation and translation of the phasing 
model, the Patterson function is used. The unique property of the Patterson function is that it 
is the same for a phasing model with the same rotation axis values, irrespective of the 
translation axis values. This implies that two models will give the same Patterson function 
wherever they are located in the unit-cell as long as they have the same rotation values. Using 
this feature of the Patterson function, the correct values for the rotation axis can be estimated. 
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Once these values are known, they can be applied along with different values of the 
translational axis to calculate structure factor intensities. These calculated values are then 
matched with experimental values to arrive at optimal translational axis values. 
 
1.7 REFINEMENT 
 Building the molecular model of a protein is closely intertwined with model 
refinement. Model refinement refers to adjusting the variable parameters of the model such 
that it optimally fits the experimentally obtained data. Refinement can be performed either in 
the real space or reciprocal space. Fitting the residues of the molecule to the electron density 
maps and regularizing the geometry is referred as real space refinement. On the other hand, 
reciprocal space refinement refers to optimising all the adjustable parameters of the model 
such that its calculated values in the reciprocal space are consistent with the experimentally 
obtained data. Since the incapacity to obtain complete phases limits the ability to obtain error 
free electron density maps, fitting residues to them cannot yield accurate models. Therefore, 
once the model has been fit to electron density maps, it is refined against the experimental 
data in the reciprocal space. As the model keeps improving during the iterative cycles of 
building and refinement, more accurate phases are available, which, in-turn, improve the 
electron density map. As the density maps improve, more residues can be added to the model 
to generate further accurate phases. The overall fit between the model and the experimental 
data is measured using the R-factor, Eq. 11, where Fobs= experimentally determined structure 
factors and Fcalc= structure factors calculated from the target structure.  
 
𝑅 = ∑ |𝐹𝑜𝑏𝑠 −  𝐹𝑐𝑎𝑙𝑐 |
∑𝐹𝑜𝑏𝑠
  
The target function that is usually used for refinement is based on maximum likelihood 
(ML). ML target functions, in most cases, tend to give better refinement as they are less 
Eq. 11 
Chapter 1. X-ray crystallography 
23 
 
susceptible to non-random errors and model bias (Pannu and Read, 1996). Traditionally, least-
square (LSQ) refinement is used for optimising the model parameters, based on experimental 
data. LSQ and ML programs adjust the model parameters to minimise the least-squares 
residual (QLS) and the ML residual respectively (Eqs. 12 and 13). 
 
𝑄𝐿𝑆 =  � (𝑋𝑜𝑏𝑠(𝑖) −  𝑋𝑐𝑎𝑙𝑐(𝑖, 𝑝(1,…,𝑝)))2𝜎𝑜𝑏𝑠2  (𝑖)𝑛𝑖=1  
 
𝑄𝑀𝐿 =  � (𝑋𝑜𝑏𝑠 (𝑖)− < 𝑋𝑐𝑎𝑙𝑐 (𝑖,𝑝(1,…,𝑝)) >)2𝜎𝑜𝑏𝑠2  (𝑖) +  𝜎𝑐𝑎𝑙𝑐2  (𝑖, 𝑝(1,…,𝑝))𝑛𝑖=1  
 
where, n = number of observations of value Xobs (X= a measurable experimental quality). 
𝜎𝑜𝑏𝑠
2  is the experimental variance of Xobs while Xcalc are the values predicted by the 
corresponding mathematical function; p is the number of parameters of the model.  
LSQ is a powerful refinement method but suffers from the fact that it cannot account 
for non-random errors in measurement. In fact, LSQ can be considered as a special case of 
ML refinement, in which non-random errors are absent. Therefore, in the initial stages of 
refinement, when the obtained phases are inaccurate, ML refinement strategy is better 
compared to LSQ. As the model accuracy improves, the calculated phases also become 
better, leading to reduction in non-random errors and the ML residual to mimic the special 







CHAPTER 2. PITUITARY ADENYLATE CYCLASE 
ACTIVATING POLYPEPTIDE RECEPTOR 1: A CLASS B G-
PROTEIN COUPLED RECEPTOR. 
 
2.1 INTRODUCTION 
 Life is characterised by ‘awareness’. An awareness of the surroundings and an 
‘active’ response to it lies at the core of any life. Millions of years ago, during their 
abiotic to biotic transition, primitive life particles became enveloped in lipid bilayer 
through mechanisms still debated about. The lipid bilayer created a favourable 
environment inside as compared to outside but did not completely insulate them from 
their surroundings. The bilayer was interspersed with molecules which allowed them 
to communicate with the surroundings and become ‘aware’ of it so as to modulate 
themselves in response. This was the inception of life. Throughout evolution, by 
replication and natural selection, one class of receptors which is the most favoured 
and prolifically used is the G Protein Coupled Receptors (GPCRs). The importance of 
GPCRs can be gauged by the fact that the human genome contains more than 800 
genes belonging to this class (Fredriksson et al., 2003) making it the largest, and 
hence, most ubiquitous and versatile among cell surface receptors. They are known to 
be the receptors of as wide ranging messengers as hormones, light, smell and taste. A 
gene can be attributed as a GPCR if it fulfils two main requirements. The first 
requirement is that it should encode for a polypeptide containing seven stretches, 25 
to 35 amino acids each, of relatively high hydrophobicity. This directly derives from 
the fact that the defining characteristic of a GPCR is that it should have seven cell-
membrane spanning α-helices, connected by alternating intracellular and extracellular 
loops. The whole receptor is placed in such a way that the N-terminus is at the outside 
of the cell while the C-terminus is at the cytoplasm. The second requirement is that 




the receptor encoded should interact with G-proteins. There exists an accepted 
mechanism of GPCR action in which there is a receptor, an effector and mediating 
between them is a transducer. The transducer in the case of GPCRs is a heterotrimeric 
G-protein, from which GPCRs derive their name. For many of the newly identified 
GPCR genes there is no direct evidence for the existence or non-existence of a G-
protein transducer. The second requirement to classify such a gene as GPCR is only 
loosely adhered to and some researchers prefer to refer to them only as 7 trans-
membrane receptors (7-TMR) instead. 
Due to the overwhelming number of GPCR genes in the mammalian genome, 
it is essential to have a lucid classification for them. Various criterions have been used 
to classify GPCRs into different groups. Some are based on their ligand binding 
properties while others rely on their phylogenetic and structural features to arrive at a 
classification scheme. The enormity of the GPCR superfamily and the added 
complexity of large sequence variation between invertebrates and mammals have 
made this task more difficult. The classification scheme that has been used throughout 
this thesis, and which is largely being followed in the research community as well, is 
based on the work of Fredriksson et al (Fredriksson et al., 2003).  
 
2.2 THE RECEPTORS 
2.2.1 Classification 
Gene relationships are often identified from sequence similarities. In the 
evolutionary timescale, genes often get duplicated either individually or in entire 
blocks as part of a chromosome. Gene duplication events are known to have produced 
variation and an increase in the repertoire of the genome. Based on this, the 2R 
hypothesis, first proposed by Ohno (Ohno, 1970) and later developed by Holland et al 




(Holland et al., 1994), says that there were two complete genomic duplications during 
vertebrate development, leading to four copies of all genes in the human genome. 
Assuming the validity of the hypothesis to search for paralogous genes in the human 
genome and examining them for evolutionary relationships through phylogenetic 
analysis, the GPCR genes have been clustered into five groups. These five groups 
form the major classes into which human GPCRs have been classified and are as 
described below. 
 
2.2.1.1 Class-A (Rhodopsin-like) 
This class comprises the largest number of receptors in the GPCR super-
family. Due to the enormous size of this class of receptors, sequence similarity among 
members is not very high. There are still some characteristically conserved regions in 
the receptors of this class because of which they have been grouped in one cluster. 
Most of the members of this class have a conserved motif made of NSxxNPxxY in 
trans-membrane (TM) region 7. In intracellular loop (IL) 2, near the TM-3 helix, there 
is another conserved motif having the sequence Asp/Glu-Arg-Thy/Phe in most of the 
members. Although the structure of bacteriorhodopsin (bR) (PebayPeyroula et al., 
1997), which also is a 7TMR, was known beforehand and was used to model the 
structure of GPCRs, bR itself is not classified as a GPCR. This is due to the reason 
that bR does not share any sequence similarity with other 7-TMRs found in 
vertebrates. In addition to this, bR does not interact with any G-protein for its activity. 
Structural information for this class was first obtained when Palczewski et al 
(Palczewski et al., 2000) solved the structure of bovine rhodopsin. It is now known 
that class A GPCRs usually have a disulphide bridge between cysteine residues from 
extracellular loop 1 and 2 which is another ‘fingerprint’ of this class. 





2.2.1.2 Class-B (Secretin receptor-like) 
This class comprises a small number of genes. There are approximately 20 
known members for this class. Their endogenous ligands are usually large peptides, 
which act as paracrine hormones. Due to this fact, class B receptors control a variety 
of important physiological processes, making them very important drug targets. 
Secretin was the first member of this group to be identified and characterised and, 
therefore, this class is also referred to as secretin-like receptors. They typically have a 
large N-terminal extra cellular domain (ECD) comprising of approximately 120 
amino acids. The ECDs usually possess multiple potential glycosylation sites. All 
ECDs in this class also have six conserved cysteines that form three disulphide 
bridges. Formation of these disulphide bridges is essential for proper folding of the 
ECD as well as its ability to bind its endogenous peptide hormone. In addition to this, 
the members of this class also form a disulphide bridge between the first and second 
extra cellular loop. The binding of ligands to the ECD can also be modified by certain 
single trans-membrane spanning domain proteins, known as receptor activity 
modifying proteins (RAMP) (Möhler and Fritschy, 1999). 
 
2.2.1.3 Class-C (Glutamate receptor-like) 
This class comprises of receptors that also possess a large ECD. The ECD 
length in this group typically ranges from 280 to 580 amino acids and is comprised of 
a large Venus fly trap module (VFTM). VFTM is a bilobular domain having a ligand 
binding site in the middle of the two lobes. Upon binding of the ligand, the two lobes 
come together and close the binding site akin to a Venus fly trap. This closed VFTM 
is then presented to the extracellular loops for activation of the receptor. The VFTM is 




connected to the 7TM by cysteine rich domain (CRD). The CRD comprises of nine 
conserved cyteines and is present in all members of this class with the GABA 
receptors being an exception. The function of the CRD is not yet well known. In 
addition, this class also has very short intra and extra cellular loops which are not 
more than 30 amino acids long. They also possess a disulphide bond between the 
cysteines at the extracellular edge of TM3 and the second extra-cellular loop. 
 
2.2.1.4 Class D (Adhesion receptor-like) 
This class is made up of members with an N-terminal ECD ranging in length 
from 200 to 2800 amino acids in length. They are named as adhesion receptor-like as 
their N-terminal ECDs appear to take part in cell-cell adhesions. This is due to the fact 
that the ECDs are made of EGF-like repeats, mucin-like and cysteine rich motifs, 
which are common in cell adhesion proteins. 
 
2.2.1.5 Class E (Frizzled/Taste2 receptor-like) 
This group is made up of two sub-clusters namely; frizzled and taste 2 
receptors from which it derives its name. The taste receptors in this group are 
significantly different from those in the glutamate receptor-like class. This can be 
gauged by the absence of a large N-terminal ECD in them which is unlikely to have 
any ligand binding domain. The frizzled receptors, on the other hand, are distinct from 
taste2 receptors and are known to have an N-terminal ECD of about 200 amino acids 
in length. The ECD is comprised of conserved cysteines and are known to bind to 
extra cellular signalling glycoproteins called WNTs. They are known to be involved 
in controlling developmental pathways by regulating cell proliferation, cell fate and 
cell polarity. 





Until the 1960s and early 70s, it was not clear if the receptors of epinephrine  
Table 2.1. Properties of the mammalian Gβ and Gγ subunits. 
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Additional 
role 





















β2 37.3 90 Nearly ubiquitous  
β3 37.2 83 Nearly ubiquitous 
Inhibition of  
activation 












γ 2 7.9 38 Brain, adrenal,  
γ 3   other (?) 
Upregulation 
of K channels 
(?) 
γ 4 8.5 36 Brain, testis  




A 2 (?) 
γ 6 7.3 25 Liver, other (?)  
 7.5 35 Brain, other(?)  
a% Amino acid identity: comparison is with the first-listed member 
of each family 




(which we now know as members of class A GPCRs) were separate from the effectors 
adenylate cyclase. 
It was assumed that they both are one and the same molecule. The Nobel prize 
winning work of Martin Rodbell (Rodbell et al., 1971) and Alfred Gillman (Gilman, 
1987, Ross and Gilman, 1977) established the existence of guanine nucleotide 
regulatory proteins that act as a transducer of information from the receptor to the 
adenylate cyclase. It is now known that these transducers are a complex of three 
proteins and are known as heterotrimeric G-proteins or Gαβγ. Gαβγ always remain 
anchored to the cytoplasmic side of the plasma membrane. The Gα subunit has 
GTPase activity while the Gβ and Gγ subunits always remain as a tight complex. The 
Gα subunit has further been divided into four different subfamilies. Gβ and Gγ are 
comprised of several members, Table 2.1, and, therefore, there can possibly be many 
different combinations of the Gαβγ heterotrimer complex. Both the Gα and Gβγ 
complexes are known to activate effectors. Tables 2.1 and 2.2 summarise the different 
types of Gα, Gβ and Gγ subunits. 
 
2.4 EFFECTORS 
The signal from an activated receptor, via a transducer, results in a cellular 
response that is brought about by certain effector molecules. GPCRs activate a variety 
of effector molecules, leading to a cascade of downstream reactions. One of the 
effectors regulated by GPCRs is adenylate cyclase. Adenylate cyclase catalyses the 
formation of the secondary messenger cAMP and, therefore, has been implicated in a 
lot of downstream effects. GPCRs, via different mechanisms, can both activate and 
deactivate adenylate cyclase. They can also activate cyclic GMP 
  




Table 2.2. Properties of the mammalian Gα subunit (Hepler and Gilman, 1992). 
 
phosphodiesterase. cGMP phosphodiesterases then effect cellular response by 
controlling the levels of cGMP second messenger. The amount of cGMP in the retina 
is crucial for visual transduction pathways (Levitzki, 1986). Another effector 
activated by GPCRs is phospholipase C. Phospholipase C effects cellular responses 
by producing the second messenger inositol-1,4,5-triphosphate (IP3). IP3 then 
mobilises intracellular stores of Ca2+ to result in a variety of effects. GPCRs are also 
known to exert direct control over ion-channels, which are also important effectors of 
several cellular functions. 
 
 




2.5 MECHANISM OF SIGNALLING 
The whole cascade of GPCR signalling can be divided into certain broad 
steps, which are described in greater detail below. Figure 2.1 illustrates the important 
steps in the mechanism.  
 
  
Figure 2.1 The G-protein cycle begins with the binding of the ligand (in 
magenta) to the receptor (in green). This activates the receptor and the 
Gαβγ complex can now interact with the activated receptor via the Gα 
subunit. The activated receptor acts like a nucleotide exchange factor 
and enables the Gα subunit to exchange its GDP with GTP. The Gα 
now comes to an active state, which results in the disassociation of the 
Gαβγ trimer into Gα and Gβγ. Both Gα and Gβγ can then act by 
binding to their respective effectors to initiate different signalling 
cascades. Gα has an intrinsic GTPase activity, which can be 
accentuated by the binding of Regulators of G-protein Signalling 
(RGS). Hydrolysis of Gα bound GTP to GDP deactivates the Gα and it 
now associates with Gβγ dimer to form the inactive Gαβγ heterotrimer. 
Figure taken from (Jones et al., 2004).  
 
2.5.1 Ligand binding and receptor activation 
The obvious first step is ligand recognition. GPCRs, being cell surface 
receptors, recognise chemical messengers outside the cell at their extracellular 
surface. Binding of a specific ligand (L) at the extracellular surface, or the 
transmembrane region via a path having an opening at the extracellular side, causes 
conformational changes in the inactive receptor (R), making it attain an active 
conformation or become active (R*). This series of events can be depicted in the 
following flow-chart. 




R + L   R*L 
The precise mode of the ligand receptor interaction depends on the class of the 
receptor. In class A receptors, the ECD is small and does not contribute much in 
ligand binding. Biogenic amine ligands bind within the helical bundle in the lipid 
bilayer of class A receptors (Ji et al., 1998). Peptide ligands that bind class A 
receptors are not postulated to typically dock deep inside the helical bundle but are 
thought to remain near the extracellular side and secure assistance from extracellular 
loops for binding.  
In class B receptors the large ECD plays an important role in ligand binding. 
The ligands for these receptors are large peptides. Ligand recognition is thought to 
follow a two step process (Hoare, 2005). In this two step process, the C-terminal part 
of the peptide hormone first binds to the peptide recognition cleft in the ECD. This 
binding creates an ‘affinity trap’ after which the N-terminal part of the peptides binds 
extracellular loops to activate the receptor. The class B GPCR ECD offers an exciting 
target for structure based drug development as the possible sites of endogenous 
peptide recognition as well as the sites in the ECD interacting with the extracellular 
loops can possibly be modulated by small molecule drugs. In addition to this, the 
large ECD of this class offers large number of sites that can be used for allosterically 
modulating either the peptide binding or the association of ECD with extracellular 
loops. This kind of allosteric modification of the ECD by a small molecule has been 
shown with Glp1R, a member of class B GPCR (Tibaduiza et al., 2001).  
In class C also, the large ECD, as expected, plays an important role in ligand 
binding. The large ECD, also known as the Venus fly trap module, is made up of two 
globular domains connected by a central hinge region. Binding of a ligand closes the 
two globular domains, like a trap, via the central hinge region. The closed trap then 




presents the ligand to the extracellular regions to activate the receptor. Dimerization 
of class C receptors in membrane is also a central theme in modulating the activation 
of the receptor. 
 
2.5.2 Gα activation 
The Gα subunit has high affinity for an activated receptor-ligand complex than 
an inactive receptor. The Gα, therefore, binds to the receptor ligand complex, which 
in-turn acts as a guanosine nucleotide exchange factor (GEF). Due to the property of 
an activated GPCR to act as a GEF, the Gα subunit exchanges its bound GDP with 
GTP, which is usually at a 10-fold higher concentration in the cytoplasm. The GTP 
bound Gα is called ‘active’ Gα as it can now disassociate from the GPCR and the Gβγ 
heterodimer and bind to the effectors to activate them.  
R*-L  R*L-Gα 
 
This step in the GPCR activation mechanism is very intriguing, as it acts as a relay 
junction, which biases the outcome of GPCR activation towards one among a few 
possible downstream events. This happens due to the preferential binding of the 
activated GPCR to certain types of Gα over others. At the molecular level, a structural 
understanding of how this preferential binding is actuated is still lacking. There is still 
no structure of an intact Gα bound to a GPCR which could shed some light on the 
molecular determinants of this step. Although some progress has been made in this 
direction by the structure of a peptide of Gα bound to opsin (Scheerer et al., 2008), 
elucidation of a GPCR-Gαβγ complex structure remains the next biggest target in the 
unravelling of the GPCR activation mechanism.  
 
GDP     GTP  




2.5.3 Activation of receptors 
In the third step, an active Gα migrates laterally in membrane and interacts 
with its effectors, including adenylate cyclase (AC), phosphilipase C, retinal cGMP 
phosphodiesterse and ion channels.  
Gα-GTP + AC  Gα-GTP-AC*  
The activated receptor can then cause a cascade of events inside the cell. The structure 
of the active Gα, in complex with the cytoplasmic domain of adenylate cyclase has 
shed light on the molecular determinants of this activation (Tesmer et al., 1997). Due 
to the GTPase activity of the Gα subunit, the GTP bound to it is quickly degraded to 
GDP. In this deactivated state, the Gα binds to Gβγ to form an inactivated 
heterotrimer. 
 
2.5.4 Signal deactivation 
The cascade of events, actuated by the active receptor-ligand conformation, is 
stopped by the deactivation of GPCR signalling which constitutes the fourth step. The 
Gβγ dimer binds to and recruits G-protein receptor kinases (GRK) from the cytosol. 
GRKs very specifically interact with those GPCRs, which are in an active 
conformation. Specific phophorylation of the active GPCRs paves the way for β-
arrestin binding. The conformational changes that occur in the activated GPCR, as a 
result of phosphorylation, result in the stabilisation of the β-arrestin-GPCR complex. 
This complex is then targeted to clathrin coated pits for internalization. The 
internalized GPCRs can later be reactivated and recycled back to membrane. Due to 
the lack of much structural information of these processes a GPCR-GRK complex or 
a GPCR-β-arrestin complex structure is also the next biggest target in the elucidation 




of the GPCR signalling mechanism. The various conformations, through which the G-
proteins are cycled during the GPCR action mechanism, are summarised in Fig. 2.2. 
 
Figure 2.2 The heterotrimeric G-protein cycle. The Gαβγ complex 
(PDB Code:1GG2) is shown at the top. Gα, Gβ and Gγ are shown in 
cyan, blue and green respectively. GDP is shown in gray with magenta 
dot surface. Switch II in Gα (represented in red), an important 
structural determinant shown in red, is sequestered away from the 
cytoplasmic milue by the Gβγ heterodimer. Right shows active Gα 
(PDB Code:1AZT). The γ phosphate makes important contacts with 
Switch II and Gβγ can now no longer bind with Gα. Bottom shows 
active Gα in complex with cytoplasmic domains of Adenylate Cyclase 
represented in brown and dark green (PDB Code: 1AZS). Switch II 
again plays an important role by interacting with AC. Right shows the 
deactivated state of Gα in the GDP bound form after the GTPase 
activity of active Gα. Switch II in this deactivated state is disordered 
and incapable of binding to any effectors. Deactivated Gα has high 
affinity with Gβγ and binds to it to form the Gαβγ heterotrimer again. 
Figure taken from Tesmer, 2010. 
 
2.6 PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 
1 RECEPTOR: CLASS B GPCR 
2.6.1 Discovery 
 The ligand for Pituitary Adenylate Cyclase activating polypeptide (PACAP) 1 
Receptor was discovered first by Akira Arimura in 1989 (Miyata et al., 1989). A 
novel polypeptide, isolated from the ovine hypothalamus, was able to stimulate 




Adenylate Cyclase activity in a culture of rat anterior pituitary cells. Sequencing a 
pure form of the extract revealed that it was a C-terminally amidated 38 amino acid 
long polypeptide and was aptly named as Pituitary Adenylate Cyclase Activating 
Polypeptide (PACAP). PACAP can also exist in a shortened form in which only the 
first 27 amino acids are present (Buscail et al., 1990). Both forms are C-terminally 
amidated. The different properties of these peptides will be discussed later.  
 PACAP binds to two different GPCR receptors (Buscail et al., 1990, Ohtaki et 
al., 1990). It also shares 68% identity with another peptide, Vasoactive Intestinal 
Peptide (VIP). Due to this high degree of similarity between them, there is an overlap 
between the receptors they recognise. Based on their relative affinity, the receptors 
recognising them have been classified into two main types. The receptors that have 
high affinity for PACAP38 and PACAP27, while much lesser for VIP, are classified 
as type I receptors or PAC1R (Cauvin et al., 1990, Gottschall et al., 1990, Lam et al., 
1990, Suda et al., 1992). Type II receptors are those that have same affinity for both 
PACAP and VIP (Gottschall et al., 1990, Lam et al., 1990). They are also known as 
VPACR. VPACR can be further divided into two sub-classes in which the receptors 
with a higher affinity for Secretin (another peptide hormone) are called as VPAC1R 
or VIP1R and the receptors with lower affinity for Secretin are called as VPAC2R or 
VIP2R. The binding affinities of the receptors for these peptides are summarised in 










Table 2.3. Binding affinities of the different classes of PACAP 
receptors. Helodermin is a peptide exclusively found in the Gila 
Monster. Peptide Histidine Isoleucine (PHI) is a VIP like peptide 




2.6.2 Structure of the PAC1R gene 
The PAC1R cDNA sequence was first determined from a pancreatic acinar 
carcinoma cell line (Pisegna and Wank, 1993) and later localized in the human 
genome to the region p15 of chromosome 7 (Brabet et al., 1996). It has an intron/exon 
arrangement that is similar to other members of the GPCR family. The activity of the 
PAC1R promoter is regulated both negatively and positively by cis-acting elements 
and also trans-acting factors, like Zac1 and estrogen receptor α (Rodríguez-Henche et 
al., 2002). The positive and negative regulatory elements form a tissue specific 
control mechanism of PAC1R expression. Diversity in PAC1R action is also caused 
due to a number of splice variants of the receptor (as described in Table 2.4). Among 
all the GPCRs, PAC1R has one of the largest number of splice variants (Dautzenberg 
et al., 1999, Lutz et al., 2006, Spongier et al., 1993). These splice variations are 
present in the intracellular (IC) loop, transmembrane (TM) domain as well as the N-
terminal extracellular domain. The localization of these splice variants is specific to a 
tissue type. Differential activation of these splice variants are thought to contribute to 




the different, and sometimes opposing, functions of PAC1R in different tissues. The 
different patterns of these splice variants to stimulate AC or PLC possibly act to fine 
tune the mechanism of signal transduction. 
In addition, the different splice variants of PAC1R also localize differently in 
different tissues. In the central nervous system (CNS), for example, while PAC1Rs 
and PAC1R-hop are expressed in cerebellar granule cells, the cerebellar glial cells 
have only PAC1Rs. The activation of PAC1R and choice of the downstream 
signalling pathway, therefore, is tightly regulated at multiple levels starting from 
binding ligand, isoform localized in the specific tissue, to the effector molecule 
activated in response to ligand recognition. This probably provides a clue as to how 
one receptor has been implicated in such a wide array of pathways. 
PAC1R is present in many areas of the central nervous system (CNS). 
Analysis of type I binding sites reveal high concentrations in many brain structures, 
including the olfactory bulb, the cerebral cortex, the septum and amygdala, the 
hippocampus, the thalamus, the hypothalamus, and the substantia nigra (Cauvin et al., 
1991, Masuo et al., 1991, Masuo et al., 1992, Suda et al., 1991, Zawilska et al., 2003). 
The PACAP and/or VIP receptors are not only present in neurons but can also be 
expressed in glial cells (Martin et al., 1992, Tatsuno et al., 1990). Analysis of the 
expression of PAC1R-mRNA shows particularly high intensity in the olfactory bulb, 
the dentate gyrus of the hippocampus, the supraoptic nucleus of the hypothalamus, the 
cerebellar cortex, and the area postrema (Hashimoto et al., 1996, Nomura et al., 1996, 
Otto et al., 1999, Shioda et al., 1997), particularly in high neurogenic areas like 
subventricular zone of the olfactory bulb or the dentate gyrus of the hippocampus. 
 




Table 2.4. The different splice variants of PAC1R and sequence 





2.6.3. Pharmacology of PACAP:PAC1R interaction: structure of PACAP 
Based on primary structure, the peptide ligands of class-B GPCRs can be 
divided into different superfamilies. PACAP is placed in a superfamily often referred 
to as PACAP/glucagon superfamily. The PACAP/glucagon superfamily is highly 
sequentially conserved and differs from the calcitonin superfamily, due to the absence 
of the N-terminal six or seven amino acid ring. Fig. 2.3 shows a multiple sequence 
alignment of the members of the PACAP/glucagon superfamily. Phylogenetic 




analysis of the superfamily reveals that PACAP is the most ancient and tightly 
conserved member (Sherwood et al., 2000).  
 
Figure 2.3. Multiple sequence alignment of PACAP/glucagon 
superfamily of peptide hormones. Residues conserved throughout the 
superfamily are indicated with red font and enclosed in blue box. 
 
The secondary structure of these peptides has been studied in aqueous as well 
as organic solvents. The peptides tend to be disordered when present in an unbound 
form in aqueous solutions. Addition of secondary structure inducing elements, like 
organic solvents or mimicking the membrane environment with micelles causes the 
peptides to assume a largely helical structure. The three dimensional structures of the 
peptides, bound to the N-terminal domain of class B receptors, show that the peptides 
assume an α-helical orientation in the bound form (Pioszak and Xu, 2008). The 
peptides are composed of amphipathic amino acids. The conformation of these 
amphipathic amino acids gets stabilized upon addition of organic solvents. Binding of 
the peptide to the N-terminal domain of receptors can also lead to the stabilization of 
the helical structure, as the hydrophobic amino acids face the receptor while the 
hydrophilic amino acids are oriented towards the outer face in the bound form.  
Class B receptor activation is believed to follow a two domain model, Fig. 2.4. 
In this two-domain model the N-terminal ECD of the receptor first interacts with the 
C-terminal portion of the peptide ligand. This interaction forms an ‘affinity trap’, 
which then makes the N-terminal portion of the peptide to interact with the 




extracellular loops of the 7-TMR (Hoare, 2005). The recognition of the C-terminal 
portion of the peptide by the N-terminal ECD of the receptor might lead to changes in 
the orientation of the extracellular loops and/or the N-terminal portion of the peptide. 
This might then trap the N-terminal portion of the peptide to bind to the extracellular 
loops which then in-turn leads to the interaction of the Gα subunit at the intracellular 
face of the GPCR. 
 
Figure 2.4. The overall scheme of the two domain model. In step 1, 
the Receptor (R) and ligand (L) are separate. L is usually a disordered 
peptide. In step 2, L assumes a largely α-helical structure in which the 
C-terminus interacts with the N-terminal domain of the receptor 
forming a complex in which contacts are made only by the N-terminal 
receptor ECD (RLN). In step 3, the peptide N-terminus makes contacts 
with the juxta-membrane portion of the receptor (RLNJ). In step 4, the 
RLNJ complex interacts with the Gα subunit at the intracellular face of 
the receptor and leads to the activation of the G-protein cycle. Figure 
adapted from Hoare, 2005. 
 
Most receptor:peptide interactions are electrostatic and hydrophobic in nature. 
The structure of receptor ECD:peptide complex available for Parathyroid hormone 
receptor (Pth1R), corticotropin releasing factor receptor (CrfR), gastric inhibitory 
peptide receptor (Gip1R) and glucagon like peptide receptor (Glp1R) show that the 
peptides interact at the surface of the receptor ECD as opposed to fitting into any 
groove on the ECD surface. At the residue level, the interactions are mainly 
hydrophobic and the amphipathic helix of the peptide interacts with receptor surface 
to bury its hydrophobic residues. The interaction is further supported by contributions 




from some electrostatic forces between the usually electropositive peptide and the 
electronegative ECD. The peptides of the PACAP/glucagon superfamily bind in a 
very similar fashion. Fig. 2.5 illustrates the binding of some selected known 
ECD:peptide complexes from this superfamily.  
 
Figure 2.5. Ligand orientation in class B GPCRs. The ligands incretin 
of Gip1R, glucagon, exendin-4 of Glp1R, Pth of Pth1R and PACAP of 
PAC1R (from NMR structure) are shown in black, orange, red yellow 
and magenta respectively. For simplicity, the surface diagram of 
PAC1R ECD alone is shown in white with the trace of PAC1R in 
green. All class B ligands of the PACAP/glucagon superfamily follow 
the same binding site and orientation. This hints a possibility of a 
unified consensus mechanism of hormone recognition and binding for 
the entire superfamily.  
 
The complex structures lack a binding groove and the interaction is largely 
superficial. All peptides in this superfamily bind in the same region. A part of the N-
terminal portion of the peptides does not interact with the ECD in these structures and 
is available to bind to the extracellular loops, in accordance with the two-domain 
model.  
 Moreover, there is a bit of redundancy in these receptors to recognise a 
particular hormone and vice-versa. The peptides that are closely related by sequence 
can be recognised by the same receptor. The binding of different peptides to the same 
receptor varies in affinity and downstream activity. In addition, while some of the 
sequentially related receptors are highly selective in binding to related hormones, 
some are not. This adds to the complexity of the GPCR activation mechanism as the 



























CHAPTER 3. MATERIALS AND METHODS 
 
3.1 PROTEIN PRODUCTION  
The extra-cellular domain of the human PAC1R (residues 21-140 and 
fragments of other lengths) was overexpressed as a maltose binding protein (MBP) 
fusion protein. Various truncations of the ECD (short isoform) were expressed for 
crystallization trials and peptide binding assays. The truncations made are 
summarized in Fig. 3.1.  
 
Figure 3.1. Sequence of the PAC1R ECD. Cysteines are marked in 
yellow box while the loop, which is absent in the short splice variant of 
the ECD, is in blue. Blue and red down arrows indicate the start 
position of the truncations, which end at the up arrows of the 
corresponding colour. Cys25 was mutated to either Ala or Ser in the 
various truncations, in accordance with the indicated colour code. 
Amino acids in blue are absent in the short isoform of the protein. 
 
MBP, without its signal peptide, was first cloned in the MCS-I of the pETDuet1 
vector (Novagen) between the NcoI and EcoRI restriction enzyme sites. Additional 
neucleotides (to code Asn-Ala-Ala) were added to the C-terminus of the MBP 
sequence. This was followed immediately by the EcoRI site, which codes Glu-Phe. 
The bacterial disulphide bond chaperone (DsbC) was then cloned into the MCS-II of 
the vector, between the NdeI and XhoI restriction enzyme sites. The E. coli DsbC 
gene has an EcoRI site in it which was mutated, using the Stratagene’s QucikChange® 
protocol, without affecting the encoded amino acid, prior to cloning into the 
pETDuet1 vector. The gene of interest, with 6xHis tag introduced in the reverse PCR 




primer, was then cloned between the EcoRI and NotI sites. This ensured that in all the 
different truncations of the receptor, the expressed protein had an N-terminal MBP 
tag, followed by a six residue linker (NAAAEF), which is connected to the PAC1R-
ECD. This was followed by a 6xHis tag at the C-terminus. These constructs were 
expressed in the Origami B (DE3) cell (Novagen). The Origami B (DE3) cell contains 
trxB/gor mutations, which create an oxidising environment in the cytoplasm, 
favouring the formation of disulphide bridges. DsbC has the ability to act both as a 
disulphide bond isomerase as well as a chaperone. Therefore, DsbC was co-expressed 
with the gene of interest to assist proper folding of the protein of interest in the 
expression host. The cells that were transformed with the construct were grown 
in LB media containing 50 µg/ml ampicillin at 37 °C until mid log phase, measured as 
0.6 < OD600 <0.8. The culture was then cooled to 16 °C and the OD600 was allowed to 
increase to 0.9-1.0. The cultures were then induced with 200 μM IPTG for 18 hrs. The 
cells were harvested by centrifugation at 3000 g. The cell pellets were either stored at 
-80 °C for future use or resuspended in buffer A [50 mM Tris (pH 7.5), 150 mM 
NaCl, 25 mM imidazole and 10% glycerol] for immediate lysis. Buffer A was added 
at the ratio of 35 ml per litre of the culture being lysed. Cells were lysed at 10,000 psi 
using a French press at 4 °C. The cell lysate was then centrifuged at 39,000 g for 20 
minutes at 4 °C and the supernatant was loaded onto a 50 ml Ni chelating sepharose 
column, which was pre-equilibrated with buffer A. The column was then washed with 
600 ml buffer A and then the bound protein was eluted with 50% buffer A and 50% 
buffer B [50 mM Tris (pH 7.5), 150 mM NaCl, 500 mM imidazole and 10% glycerol] 
using an AKTA FPLC system The eluted sample was then loaded onto a 50 ml 
amylose column. The column was then washed with 150 ml buffer C [50 mM Tris 
(pH 7.5), 150 mM NaCl] and then subsequently the protein was eluted using a 




gradient of buffer C and buffer D [50 mM Tris (pH 7.5), 150 mM NaCl, 10 mM 
maltose] from 0 to 100 % over 200 ml volume. 
 To ensure homogenous intramolecular disulphide bond formation and to 
eliminate any intermolecular disulphide bridges, the eluted protein was subjected to 
disulphide bond shuffling, in which, the eluted protein was mixed with purified DsbC 
(Sec. 3.2) in a 1:1 molar ratio, in addition to 1 mM reduced and 1 mM oxidized 
glutathione (GSH and GSSG, respectively) at 20 °C for 12-14 hrs. Various parameters 
involved in the re-shuffling reaction had to be optimised to achieve best results for the 
protein of interest. The final conditions for re-shuffling were chosen after performing 
an initial trial using the following parameters: 
i) Protein – DsbC + 1mM GSH + 1mM GSSG 
ii) Protein – DsbC + 1mM GSH + 10mM GSSG 
iii) Protein – DsbC + 10mM GSH + 1mM GSSG 
iv) Protein + DsbC + 1mM GSH + 10mM GSSG  
v) Protein + DsbC + 1mM GSH + 1mM GSSG 
vi) Protein + DsbC + 10mM GSH + 1mM GSSG 
The final concentration of the protein was 1 mg/ml. DsbC was added at a 
molar ratio ratio of 1:1. 1 M Tris (pH 7.5) and 5 M NaCl were added such that after 
adding water to top-up the reaction mixture to 100 µl, the final concentrations of Tris 
and NaCl were 50 and 150 mM, respectively. The 100 µl reaction tubes were then 
divided into two tubes of 50 µl each. One set was incubated at 4 °C while the other 
was incubated at 20 °C for 12-16 hrs before analysing the results by running a native 
PAGE. Each lane of the native PAGE was loaded with exactly 5 µg of the protein to 
enable accurate comparison of the band intensities.  




Based on the gel (Fig. 4.2), the condition chosen for large scale re-shuffling of 
the protein for all purifications was: 1 mM GSH + 1 mM GSSG + DsbC at 20 °C. For 
purifying any new truncation, the protein samples were initially analyzed in a similar 
manner before performing a large scale re-shuffling. As most of the truncations and 
mutations designed on the ECD were only for a few amino acids, no major change in 
the most favourable re-shuffling condition was observed. 
 The shuffled protein was then loaded onto the 50 ml Ni chelate column to 
remove untagged DsbC. After washing the column with 150 ml buffer A, the bound 
protein was eluted with 50% buffer B. The protein was then concentrated and loaded 
onto an S200 column, equilibrated with buffer E [10 mM Tris (pH 7.5), 50 mM NaCl, 
1 mM maltose and 1 mM EDTA] for size exclusion chromatography. The obtained 
protein was >95% pure and homogenously folded as confirmed by SDS- and native 
PAGE. 
The non-conserved Cys25 in the PAC1R-ECD was mutated to either Ser or Ala in 
order to prevent it from forming any intra- or inter-molecular disulphide bond. The 
QuickChange site-directed mutagenesis kit from Stratagene was used to make point 
mutations in the ECD gene. Fully overlapping primers, which contained the desired 
point mutation to change the codon for Cys25 to the most preferred codon for either 
Ser or Ala, were used to PCR the entire expression plasmid. Phusion High-fidelity 
DNA polymerase from Finnzymes was used for the PCR reaction. In the first step, the 
PCR was run with ~20 ng of template to make copies of the clone containing the 
mutation using the following protocol. 
1.  98 °C 30 sec, 1 cycle 
2.  98 °C 10 sec, 55 °C 20sec, 72 °C 4.5 min 20 cycles 
3. 72 °C 10 min, 1 cycle 




4. 4 °C hold 
After PCR, 12 µl of the product was digested with 0.8 µl of the restriction 
enzyme DpnI (NewEngland Biolabs) for 2 hrs. The digestion with DpnI ensured 
removal of the PCR template which does not contain the mutations. 2 µl of the 
digested product was then transformed into competent Omnimax™ cells from 
Invitrogen. The plasmids from the colonies that were obtained next day were 
sequenced to confirm the presence of the mutation. 
 
3.2 DSBC PURIFICATION 
 The DsbC gene was cloned into the pETSUMO vector (Invitrogen) with an 
additional N-terminal His tag to the DsbC protein. The clone was transformed into 
BL21 (DE3) competent cells. The cells were grown in LB media until the OD600 
reached 0.8. The cells were then cooled to 16 °C and were induced with 100 µM 
IPTG before the OD600 reached 1.0. After induction, the cells were cultured at 16 °C 
for 12-16 hrs. Cells were then harvested by centrifugation at 3000 g. The cell pellets 
were then either frozen at -80 °C for later use or resuspended with buffer F [50 mM 
Tris (pH-7.5), 150 mM NaCl and 2 mM β-mercaptoethanol (BME)]. In general, 35ml 
of buffer F was used for 1 L of cell culture. The cells were then lysed using the 
French press at 10,000 psi. The cell lysate was then centrifuged at 39,000 g at 4 °C. 
The supernatant was loaded onto a Ni-chelating column for affinity purification. The 
column was then washed with 600 ml of buffer F and then the protein was eluted 
using 50% buffer F and 50% buffer G [50 mM Tris (pH-7.5), 150 mM NaCl, 2 mM 
BME and 500 mM imidazole]. Sumo-protease (in-house supply) was then added to 
the protein at a weight (protease):weight (DsbC) ratio of 1:1000 and kept for dialysis 
at against 4 L of buffer H [50 mM Tris (pH 7.5), 150 mM NaCl, 2 mM dithio-threitol 




and 50% glycerol). After dialysis for 12-16 hrs, the protein was frozen in small 
aliquots at -80 °C until required. 
 
3.3 CRYSTALLIZATION, DATA COLLECTION AND STRUCTURE 
DETERMINATION 
The purified PAC1R protein was concentrated to 30 mg/ml and screened for 
crystallization using commercial screens (Hampton Research, Jena Biosciences and 
Qiagen) with a Phoenix robot (Art Robbins Instruments). The reservoir was filled 
with 75 µl of the solution and 0.2 µl of the protein at 30 mg/ml with equal amount of 
the crystallization condition was added onto the sitting-drop well. CrystalMation 
Intelli-Plate 96-3 plates, which have been designed for sitting drop vapour diffusion 
crystallization experiments, were used for initial screening. Initial crystals were 
obtained in a few conditions but the condition that gave the best data and which was 
ultimately used to solve the structure of PAC1R-ECD was identified in condition D9 
of JCSG++L from Jena Biosciences. After the identification of the condition in the 
96-well plate, grid screens were set in hanging drop as well as sitting drop vapour 
diffusion plates, using VDX plates with sealant from Hampton Research, at 20 °C. 
The structure was solved with crystals grown in 25.5% PEG4000, 15% glycerol and 
170 mM ammonium sulphate. Crystals first appeared after three days and grew for 
one week, after which they were transferred to a fresh drop and allowed to equilibrate 
by vapour diffusion against 1 ml of reservoir solution overnight. The crystals were 
then flash cooled, without any additional cryo-protectant, by plunging directly in 
liquid nitrogen. X-ray diffraction data were collected at the LS-CAT sector beamline 
21ID-F (LS-CAT), Advanced Photon Source synchrotron (USA). The data were 
processed by HKL2000 (Otwinowski and Minor, 1997). C-truncate was then used to 




generate the structure factors (Padilla and Yeates, 2003). The structure was solved by 
molecular replacement using the previously reported structure of MBP-PTH1R 
(PDBId: 3C4M) as a model in the PHASER program (McCoy et al., 2007) of CCP4 
(Bailey, 1994, Potterton et al., 2003). Only the MBP domain was first used as a search 
model. After a solution for MBP was chosen the PTH1R-ECD was used as the search 
model in the next step. Performing the search with MBP revealed clear electron 
density for the ECD region as well which then further improved after the ECD search. 
The ECD of PTH1R was truncated in accordance with the corresponding residues in 
PAC1R-ECD in order to avoid atom clashes during the acceptance of the results. Coot 
(Emsley et al., 2010) and Refmac5 (Murshudov et al., 1997) were subsequently used 
for iterative model building and refinement, respectively. The residues of PTH1R-
ECD, which was used as search model in Phaser, were mutated and the linker 
connecting ECD with MBP were added during iterative refinement and build cycles. 
Restrained refinement was used in Refmac5 to refine the initial models. Waters were 
added in the model using Coot. After the model reached an Rfree of 25% the 
subsequent refinements were performed using Translation, Libration and Screw (TLS) 
and restrained refinement in Refmac5 (Winn et al., 2001). The radius of convergence 
can be increased by adding restraints like rigid-body refinement, density averaging 
(Kleywegt and Read, 1997), non-crystallographic symmetry constraints (Kleywegt, 
1996) and torsion-space refinement (Rice and BrüNger, 1994) to the model. In small 
molecular crystallography, thermal parameters are refined anisotropically (6 thermal 
parameters per atom), owing to a small number of atoms and a favourable parameters 
to reflection ratio. However, in protein crystallography, only isotropic thermal 
refinement is possible for medium resolution structures. TLS parameterization, 
however, provides an ideal compromise between the two cases and a true 




representation of the model would be possible. It assumes regions/domains in the 
protein to behave as a pseudo-rigid body. It, therefore, considers collective rather than 
independent atomic variables to represent the model to reduce the refinement 
parameters. The entire model was divided into two TLS groups for performing the 
TLS refinement. Based on the knowledge of other MBP-ECD structures (Pioszak et 
al., 2008, Pioszak and Xu, 2008) MBP and maltose were kept as one TLS group while 
the ECD was made the second TLS group. The residue in the linker region between 
MBP and ECD which displayed a sharp bend was chosen as the junction point of the 
two TLS groups. All other hetero atoms were excluded from TLS refinement. 
ANISOU factors were generated, after the final round of refinement, using TLSANL 
(Howlin et al., 1993). The geometry of the final model was verified using 
PROCHECK (Laskowski et al., 1993). 
 
3.4 PEPTIDE BINDING ASSAY 
The binding of PAC1R with a 35 residue PACAP peptide was analysed using 
the histidine detection kit of AlphaScreen luminescent proximity assay from 
PerkinElmer, Fig. 3.2. All binding assays were performed without cleaving the MBP 
tag from the receptor ECD to ensure maximum correlation between the observed 
structure and the functional assays. 
 a    b 
  




Figure 3.2 Cartoon description of the mechanism for detecting 
receptor:ligand interaction in the alphascreen assay. (a) Interaction of 
moieties A and B brings the donor and acceptor beads close which 
allows the transfer of singlet O2 between them resulting in a signal. (b) 
No interaction between moieties A and B does not allow the transfer of 
the short lived singlet O2 between the beads, resulting in no detection 
of output signal. Figure adapted from PerkinElmer’s manual. 
 
 Using its C-terminal His tag, PAC1R was bound to Ni-chelate coated acceptor 
beads (10 μg/ml), to a final concentration of 80 nM. Similarly, biotinylated PACAP 
was bound to streptavidin coated donor beads (10 μg/ml) to the final concentrations of 
80 nM. 1M MOPS (pH-7.5) and 40mg/ml BSA were then added to the reaction 
mixture such that after adding water to make up the desired reaction volume, the final 
concentrations in the reaction mixture are 50 mM MOPS (pH-7.5) and 150 mM NaCl. 
The protein and peptide were pre-incubated with the respective beads for one hour to 
ensure maximal binding to the beads. They were then mixed together, in equal 
volumes, which brought the final concentration of the two kinds of beads to 5 µg/ml 
and of the protein and peptides to 40 nM leaving the concentrations of MOPS, NaCl 
and BSA unchanged. They were then allowed to interact with each other at 20 °C for 
five hours. To perform competitive binding assays, 120 μM of the untagged 
competing peptides were added at time 0 of the five hour protein-peptide interaction 
period. All interactions were performed such that the final background buffer 
condition had 50 mM MOPS pH 7.4, 150 mM NaCl and 7 mg/ml BSA. The binding 
signals were measured in a 384-well microplate using an Envision 2104 plate reader 
(PerkinElmer). The obtained data for competitive peptide binding were fit as a non-
linear regression curve using the variable slope dose-response inhibition analysis 
using the Prism5.0 (GraphPad). To ensure the specificity of the competing peptides, a 
control peptide of biotin-Gly6-His6 was used in the same assay setup. It was made 




sure that the competing peptide, at concentrations even higher than those used in the 
actual assay, does not affect the binding signal of the control peptide. 
  
3.5 DOCKING OF PACAP8-27 TO PAC1R-ECD 
The coordinates of PACAP (residues 8-27, hereafter PACAP8-27) were 
obtained from the NMR structure of the micelle bound form of the peptide (PDB 
code:2d2p). A course grid, covering the entire PAC1R-ECD, was used in a blind 
search for the binding site of the rigid peptide (Table 3.1). The grid box was kept 
large enough to allow Autodock 4.2 (Morris et al., 2009) to search all possible ECD 
interacting orientations. 
Table 3.1. Grid parameters used for AutoGrid during the initial blind 
search for the peptide binding site.  
 
Grid Parameters Description 
npts 126 117 112  # num.grid points in xyz 
gridfld 3N94ECD_ss_noaltconfig.maps.fld # grid_data_file 
spacing 0.269444444444 # spacing(A) 
receptor_types A C HD N OA SA # receptor atom types 
ligand_types A C OA N SA HD # ligand atom types 
receptor 3N94ECD_ss_noaltconfig.pdbqt # macromolecule 
gridcenter 2.567 12.875 -8.029  # xyz-coordinates or auto 
smooth 0.5  
# store minimum energy w/in 
rad(A) 
map 3N94ECD_ss_noaltconfig.A.map # atom-specific affinity map 
map 3N94ECD_ss_noaltconfig.C.map # atom-specific affinity map 
map 3N94ECD_ss_noaltconfig.OA.map # atom-specific affinity map 
map 3N94ECD_ss_noaltconfig.N.map  # atom-specific affinity map 
map 3N94ECD_ss_noaltconfig.SA.map  # atom-specific affinity map 
map 3N94ECD_ss_noaltconfig.HD.map # atom-specific affinity map 
elecmap 3N94ECD_ss_noaltconfig.e.map # electrostatic potential map 




dsolvmap 3N94ECD_ss_noaltconfig.d.map # desolvation potential map 
dielectric -0.1465  
# <0, AD4 distance-dep.diel;>0, 
constant 
 
The Lamarkian GA was used as the search algorithm to locate the peptide 
docking site. 100 GA runs, having a population size of 300, were performed before 
clustering the obtained solutions (Table 3.2). The top cluster having rank 1 comprised 
of 23/100 solutions, the highest among the 10 obtained clusters. In this cluster, 
PACAP was positioned at the same site as in other class B GPCR:ligand complex 
structures. 
 
Table 3.2. Docking parameter file describing the parameters used to 
perform the Lamarkian Genetic Algorithm search in AutoDock4.2.  
 
Docking Parameter Description 
tran0 random # initial coordinates/A or random 
axisangle0 random # initial orientation 
dihe0 random # initial dihedrals (relative) or random 
tstep 2.0 # translation step/A 
qstep 50.0 # quaternion step/deg 
dstep 50.0 # torsion step/deg 
torsdof 90 # torsional degrees of freedom 
rmstol 2.0 # cluster_tolerance/A 
extnrg 1000.0 # external grid energy 
e0max 0.0 10000 # max initial energy; max number of retries 
ga_pop_size 300 # number of individuals in population 
ga_num_evals 2500000 # maximum number of energy evaluations 
ga_num_generations 
27000 # maximum number of generations 
ga_elitism 1 # number of top individuals to survive to next 





ga_mutation_rate 0.02 # rate of gene mutation 
ga_crossover_rate 0.8 # rate of crossover 
ga_window_size 10 #  
ga_cauchy_alpha 0.0 # Alpha parameter of Cauchy distribution 
ga_cauchy_beta 1.0 # Beta parameter Cauchy distribution 
set_ga # set the above parameters for GA or LGA 
sw_max_its 300 # iterations of Solis & Wets local search 
sw_max_succ 4 # consecutive successes before changing rho 
sw_max_fail 4 # consecutive failures before changing rho 
sw_rho 1.0 # size of local search space to sample 
sw_lb_rho 0.01 # lower bound on rho 
ls_search_freq 0.06 # probability of performing local search on 
individual 
set_psw1 # set the above pseudo-Solis & Wets 
parameters 
unbound_model bound # state of unbound ligand 
ga_run 50 # do this many hybrid GA-LS runs 
analysis # perform a ranked cluster analysis 
 
The grid was then made finer and smaller. The new grid was still made to 
cover the entire face of ECD where PACAP docked in the first run. The bonds in the 
side chains of Lys20'and Tyr13' in PACAP8-27 were made rotatable to allow for a 
better fit. This yielded a total of 7 rotatable bonds. The new run was performed using 
a search criterion similar to the first run except that the number of GA runs was raised 
to 200. Guided by the knowledge of the other ECD:peptide complex structures, a 





CHAPTER 4. RESULTS 
 
4.1 PROTEIN PRODUCTION 
The extracellular domain (ECD, residues 21-153) of human PAC1R was 
expressed in Origami B (DE3) cells. All members of the class B GPCRs have six 
conserved cysteines (Fig. 4.1). These six conserved cysteines form three disulphide 
bridges as discussed in the previously solved GIP1R structure (Parthier et al., 2007). 
These disulphide bridges hold the conformation of ECD tightly, with minimum 
structural flexibility. In addition to the conserved cysteines, PAC1R has one more 
cysteine residue at a non-conserved position. 
To avoid any unessential or misformed disulphide bond, the non-conserved 
Cys25 was mutated to either serine or alanine in all our constructs. The gene for the 
variable lengths of human the PAC1R ECD used for all experiments was cloned 
downstream of the maltose binding protein (MBP) tag in the multiple cloning site 1 
(MCS1) of the pETDuet-1 vector. In summary, the final expressed protein was MBP-
NAAAEF-PAC1R-H6, which contains the underlined linker between MBP and the 
main protein. A bacterial disulphide bond chaperone (DsbC) was cloned in MCS2 of 
the vector to assist proper folding of the protein of interest during expression. The 
protein was purified with affinity chromatography using affinity tags at both ends. 
This was essential to ensure the removal of prematurely truncated proteins, which 
arise due to the translational stops that are common when human proteins are 
expressed in E. coli. In addition, having affinity tags at both ends also prevents co-
purification of truncation products, which could be formed during or after cell lysis. 
The recombinant protein was first purified using Ni-chelation chromatography and 
then followed by amylose column purification. 




Figure 4.1. Multiple sequence alignment of all class B GPCR ECDs. 
The invariant residues are shown in white with black background. 
Conserved residues are shown in bold inside black bordered box. The 
alignment clearly shows that all ECDs have six conserved cysteines. 
PAC1R has one extra cysteine at position 25 which was mutated to 
alanine (PAC1Rs numbering). Alignment was performed with MAFFT  
(http://www.ebi.ac.uk/Tools/mafft/) and the figure was prepared using 
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4.1.1 Disulphide shuffling 
 
(a)    (b) 
   
Figure 4.2. Native gel of the re-shuffling conditions incubated at (a) 20 
°C and (b) 4 °C. Lane 1 is DsbC + 1mM GSH and 1mM GSSG. Lanes 
2-7 of (a) are conditions i-vi from above. (b) Lane 8 contains DsbC. 
Lanes 9-14 are conditions i-vi mentioned above. Lane 15 is the protein 
without performing any re-shuffling. Lane 16 is the protein incubated 
with 2mM DTT for 30 mins. prior to loading. Red bordered boxes 
indicate DsbC and the black bordered boxes indicate single 
conformation of PAC1R-ECD. 
 
Analysis of all the lanes in fig 4.2 showed that lane 6 gave the best results. 
Lane 6 has only a single band of PAC1R-ECD (indicated by black bordered box). In 
addition, there are no smears or minor bands of a different conformation similar to the 
band of the major conformation. All the other lanes, except lane 7, showed the 
presence of small amounts of heterogenous conformation. The only bands of 
heterogenous conformation in lane 6 were at a level of very high molecular weight. 
These can easily be separated using size exclusion chromatography (SEC). Lane 16 
shows a completely reduced conformation of PAC1R-ECD which migrates slower on 
the native PAGE due to its relaxed conformation.  
 
High protein purity is a primary prerequisite for crystallization. Also, equally 
pivotal for crystallization is the conformational homogeneity of a sample. Proteins, 
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being conformationally flexible and dynamic, can fold into more than one 
conformation. Proteins expressed recombinantly in foreign hosts have a higher 
tendency to misfold due to non-native micro-environment and mechanisms of protein 
processing. Therefore, in order to check the conformational homogeneity of PAC1R, 
5 µg of the protein was run in a Native PAGE. The sample showed a smear, which 
clearly confirmed the presence of multiple conformations. This smearing was 
attributed to misformation of disulphide bonds. To assure proper protein folding, an in 
vitro re-shuffling of disulphide bonds was performed. The refolded protein was 
further purified using size exclusion chromatography to separate minute amounts of 
non-homogenous conformations. The gel filtration profile gave a comparatively much 
larger peak at the size of a monomer and relatively small (approximately 20% of the 
larger peak) peak at a very high molecular weight range, which, when analysed on 
native PAGE, appeared to be non-homogenous high molecular weight aggregates 
(Figs. 4.3 and 4.5). 
The conformational homogeneity of the finally obtained protein was analysed 
in non-reducing native PAGE for improvements during the steps of purification and 
disulphide reshuffling (Fig. 4.4). It is apparent that initially the protein had multiple 
conformations and appeared as a smear in native PAGE but after refolding it gives a 
single band with no smear. The ability of all molecules in the protein sample to 
migrate together in a native PAGE indicates its conformational homogeneity, which, 
in turn, is indicative of this conformation being the global minimum in the energy 
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(a)      (b) 
  
(c)      (d) 
  
Figure 4.3. Chromatograms of PAC1R purification. (a) Ni-chelate 
affinity column1 (b) Amylose affinity column (c) Ni-chelate affinity 
column 2 (d) Size-exclusion chromatography column. 
 
(a)      (b) 
 
Figure 4.4. (a) Native PAGE of MBP-PAC1R-H6 during various 
stages of purification. The lanes are labelled. Homogenous 
conformation of the protein sample could not be obtained without 
reshuffling its disulphide bonds. The few bands of less intensity in the 
lane containing Ni-column 2 elute were separated from the major band 
of much larger intensity by size exclusion chromatography. (b) SDS-
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PAGE of the SEC column fractions. Lanes 1-8 are from the first, 
minor, peak which show some high molecular weight contaminants. 
Lanes 9-14 are from the second, major, peak which show 
approximately >95% pure protein. 
 
The homogeneity and quality of the final protein after SEC was judged by the 
native PAGE in Fig 4.5. 
 
Figure 4.5. Native PAGE of the SEC fractions. The final SEC peak is 
completely conformationally homogenous. 
 
4.2 HORMONE BINDING ASSAY 
Further verification of the quality of the final protein was performed by 
analysing its activity and comparing it with the previously reported values of ligand 
affinity. The AlphaScreen assay (PerkinElmer), which provides an elegant way of 
measuring IC50 values, was used to test the activity of the protein. IC50 is the measure 
of the ability of a compound to inhibit the biological or biochemical activity of a 
protein molecule. It is an important criterion to evaluate and compare the 
pharmacokinetics of different compounds in the drug development industries. The 
IC50 value of a compound is defined as the half maximal concentration required to 
inhibit a biological or biochemical function. In an AlphaScreen assay setup a labelled 
Chapter 4. Results 
63 
 
peptide / ligand and its receptor can be immobilized onto donor and acceptor beads. 
The proximity of the two beads upon receptor:peptide interaction can then be assayed. 
An unlabelled peptide, when added, then competes for binding with the immobilized 
peptides, at the receptor’s active site, thus, inhibiting the signal. Plotting the dose-
response curve for the unlabelled peptide gives its IC50 value. Higher values of IC50 
would typically mean low affinity and vice versa.  
 
Figure 4.6. Interaction of B-PACAP with MBP-PACAP(25-140)-H6 
assayed using alphascreen. Concentration of B-PACAP was kept 
constant at 40nM while the concentration of the MBP-PACAP(25-
140)-H6 was increased from 40nM to 202.3nM with an increment of 
1.5 times each. Photon counts are plotted on the y-axis. As the 
concentration of the receptor increases the binding signal also 
increases and then reaches saturation.  
 
The ability of the C-terminal domain of PACAP to bind the ECD (in 
accordance with the two domain model) was first tested to ensure the functional 
activity of the receptor. Fig. 4.6 shows the concentration dependant interaction of 
PACAP with PAC1R ECD. In this experiment, the concentration of biotin-PACAP 
(residues 6-38) was kept constant at 40 nM in all reaction conditions. The 
concentration of MBP-PAC1R(25-140)-H6 was increased as 40, 60, 90, 135 and 200 
nM. The ability of the peptide:receptor complex to form a complex in a concentration 
dependant manner and then to reach saturation at higher amounts indicates that the 
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purified protein is functional and retains its biochemical activity. Furthermore, the 
pattern was also indicative of the fact that the signal recorded in this setup of 
Alphascreen assay had little contribution from any non-specific interaction between 
the donor and acceptor beads. 
 
Figure 4.7. Competitive Alphascreen assay with unlabelled PACAP as 
a competitor for binding to 40 nM biotin-PACAP (6-38)-NH2 and 40 
nM MBP-PAC1R (25-140)-His6 in the presence of 5 μg/ml beads. 
Dashed, dotted and solid curves represent un-labelled PACAP (8-38), 
PACAP (12-27) and PACAP (15-31) as competitors, respectively. 
 
Biotin-PACAP(6-38) binds with the ECD, bringing the donor and acceptor 
beads close to each other. In the Alphascreen assay, the proximity of the beads gives a 
maximal signal. Due to the nature of the assay, the intensity of the signal by itself is 
not an accurate indicator of the affinity of the peptide with the hormone. Nevertheless, 
the assay provides an elegant setup to test the ability of inhibitors to inhibit this 
interaction in a concentration dependent manner. This ability allows the Alphascreen 
assay to be used to estimate the affinity of an inhibitor towards its receptor. 
Unlabelled ligands can be used to compete with labelled ligands for interaction with a 
receptor and act as inhibitors of the measured signal. Different truncations of PACAP, 
each still retaining the essential ECD binding region, were used to compete for 
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binding with the ECD to draw a dose response inhibition curve, Fig 4.7. This allowed 
more rigorous analysis of the binding pattern of the peptide ligands.  
The concentration of competing ligands that was required to bring half-
maximal inhibition were used to calculate IC50 values using GraphpadPrism 5.0. The 
obtained IC50 values are summarised in Table 4.1.  
Table 4.1. Summary of the IC50 values of PACAP 8-38, 12-27 and 
15-31. The indicated peptides were used to compete with labelled 
MBP-ECD and PACAP6-38 to obtain dose response curves.  
 
 PACAP8-38 PACAP12-27 PACAP15-31 
 
LogIC50 -5.647 -5.232 -5.132 
IC50 2.25E-06 5.86E-06 7.38E-06 
    
Degrees of 
Freedom 
30 30 30 
R² 0.9513 0.9915 0.9788 
Absolute Sum of 
Squares 
1930 383.5 975.8 
Number of points 
analyzed  
33 33 33 
 
The IC50 values of different truncations were very similar to each other. This 
correlates with previous studies, which have indicated that this region contributes 
towards affinity of receptor interaction, as reviewed by (Vaudry et al., 2009). Gradual 
truncation of the N-terminus of a peptide ligand also gradually decreases the affinity 
of the hormone for the receptor. The obtained values of IC50 for MBP-PAC1R (25-
140)-H6 were in the range of 1-10 µM, which also correlates well with similar values 
from other class B GPCR ECDs (Parthier et al., 2007).  
 
4.3 CRYSTALLIZATION OF PAC1R 
 MBP-PAC1R (25-140)-H6 was crystallized at 20 °C by the vapour diffusion 
hanging drop method. The initial conditions for crystallization were identified using 
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commercial screens from Hampton Research, Qiagen and Jena Biosciences. The final 
crystals used for structure determination were grown using a grid screen based on 
condition D9 of the Jena Biosciences JCSG++L sparse matrix screen, with 25.5% 
PEG4000, 15% glycerol and 170 mM ammonium sulphate. These components, in the 
grid screen, were varied one at a time while keeping the other parameters constant. 
PEG4000, glycerol and ammonium sulphate were varied from 20-28%, 10-17% and 
120-200mM, respectively to optimize the size and shape of the crystals. 
 
Figure 4.8. Crystals of MBP-PAC1R (25-140)-H6 grown in 25.5% 
PEG4000, 15% glycerol and 170 mM ammonium sulphate at 20 °C 
using the vapour diffusion hanging drop technique. 
 
 The crystals appeared after three days and grew in size for about a week. The 
best diffraction quality crystals were obtained by picking the one week old crystals 
and soaking them in fresh reservoir solution for about two to three days. Crystals 
grew as a cluster of thick needles or plates joined in the middle and radiating out in all 
directions (Fig 4.8). Single crystals were separated from the cluster. The 
crystallization solution itself, with its high concentrations of glycerol and PEG 4000, 
acted as a cryo-protectant. A crystal of suitable size was flash-cooled in liquid N2. 
Diffraction data (360° data with 1° oscillation per frame) were collected at beamline 
LS-CAT 21ID-F at the Advance Photon Source in Argonne National Laboratory. 
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4.4 STRUCTURE OF MBP-PAC1R (25-140)-H6 
4.4.1 Crystal packing 
 The structure of MBP-PAC1R(25-140)-H6 was solved in the P212121 space 
group. The data collection, structure determination and refinement statistics are 
summarized in Table 4.2. There is one molecule in the asymmetric unit. The solvent 
content in the crystal, as determined by Mathew’s coefficient, is 40%. The data were 
scaled until a resolution of 1.9 °A using I/σ(I) and Rsym as criteria. MBP, in addition 
to being highly soluble, aids in the process of crystallization. MBP has the ability to 
make numerous crystal contacts which increases the probability of obtaining crystals 
for MBP-tagged proteins. 
 
Table 4.2. Data collection, structure determination and refinement 
details. Values in parentheses are for the last shell (1.98-1.9 Å).  
 
 
Space group     P212121 
Unit-cell parameters (Å):   a = 45.98, b = 92.15, c = 105.41  
      
Data collection 
Wavelength (Å)    0.98972 
Resolution range (Å)   50.0-1.9 
Total no. of observed reflections  579,761 
Total no. of unique reflections  42,645 
Redundancy    13.6 (12.0) 
Completeness (%)    100 (100) 
Rsyma      0.090 (0.570) 
Overall I/σ(I)    28.8 (4.7) 
 
Structure determination 
Method     Molecular replacement 
Model     PDB ID: 3C4M 
 
Refinement 
Resolution range (Å)    50.0-1.9 
Rworkb     0.176 
Rfreec     0.216 
RMSD bond lengths (Å)   0.020 
RMSD bond angles (º)   1.7 
Average B-factors (Å2): 
 Protein atoms (5724 atoms)  34.04 
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 Water molecules (323 atoms)  35.35 
Ramachandran plot: 
 Most favoured regions (%)  93.2 
 Additional allowed regions (%) 6.8 
 
aRsym = hkl i [|Ii (hkl) - <I(hkl)>|]/ hkl Ii(hkl)  
bRwork = |Fobs - Fcalc| / |Fobs| where Fcalc and Fobs are the calculated and observed 
structure factor amplitudes, respectively. 
cRfree is same as Rwork, but 5.0% of the total reflections, chosen at random, were 
omitted during refinement. 
 
Most of the crystal contacts in the MBP-PAC1R (25-140)-H6 crystal are 
between the MBP molecules which largely contribute to hold the crystal together. The 
crystal contacts are also mediated, to a comparatively less extent, by MBP-ECD 













Figure 4.9. Crystal contacts in the structure of MBP-PAC1R (25-140)-
H6. MBP is shown in cyan while PAC1R (25-140) is in green. MBP 
acts as a crystallization chaperone by making favourable crystal 
contacts with other MBP molecules as well as ECD. Only minor 
contribution comes from ECD-ECD contacts.  
 
90° 
Chapter 4. Results 
69 
 
The flexibility of the linker between MBP and ECD is also very crucial for the 
formation of crystal. Gradual truncation of the N-terminal portion of the ECD had to 
be performed in order to find a construct that allowed favourable flexibility. Several 
truncations of the N-terminal portion (from 21 to 26) were tried. Cys25 was mutated 
to either Ala or Ser using the QuickChange site-directed mutagenesis kit (Stratagene). 
Altering the length of the N-terminal portion of the receptor changes the helical 
propensity of the polypeptide stretch comprising the C-terminal helix of MBP, linker 
between MBP and ECD, and the N-terminal helix of ECD. This can be gauged by the 
fact that while the structures of 3 different truncation constructs gave no apparent 
differences in the structures of MBP or ECD, the relative orientation of these two 
domains was different. PAC1R 30-150-H6 had two molecules in the ASU in which 
the relative orientation of MBP and ECD was different in the two molecules. PAC1R 
26-140, on the other hand, formed a contiguous and straight helix extending from the 
C-terminal helix of MBP to the N-terminal helix of ECD, which included the 5 amino 
acid linker between them. The best data and structure was ultimately obtained with 
PAC1R 25-140, and this was ultimately used to interpret the structural features of 
PAC1R-ECD. This protein packed in the crystal such that the contiguous helix 
extended from MBP to ECD but with a sharp bend in the linker, bringing the ECD 







Chapter 4. Results 
70 
 
4.4.2 Fold of PAC1R-ECD  
 
 
Figure 4.10. Cartoon representation of the overall fold of PAC1R-
ECD. The three disulphide bonds are shown as sticks. Major structural 
elements are labelled. 
 
The overall crystal structure of PAC1R (Fig. 4.10) is very similar to other 
previously determined ECD structures of CRFR1 (Pioszak et al., 2008), GLP1R 
(Runge et al., 2008), GIP1R (Parthier et al., 2007) and PTH1R (Pioszak and Xu, 
2008). The three conserved disulphide bonds hold the core of the PAC1R polypeptide 
together in a sandwich like configuration (Parthier et al., 2007). The N terminus starts 
with an α-helix that begins from Ala25 and continues until Asn48. This is followed by 
a short anti-parallel β sheet, held below the helix by a disulphide bridge. This is 
sandwiched from below by another anti-parallel β-sheet and held by a disulphide 
bond that bridges β5 to the loop just preceding β1. The orientation of the loop 
between β3 and β4, relative to α-helix 2, is constrained by the third disulphide bridge 
between Cys77 and Cys113. The loop between β3 and β4 contains two 310 helices. 
The sequentially invariant amino acids (Fig. 4.1), among the class B GPCR ECDs 
(apart from the disulphide bonded cysteines), Asp59, Trp64, Pro78, Gly101 and 
Trp102, are placed in the structural core of PAC1R (Fig 4.11).  




Figure 4.11. Superimposition of the sequentially conserved amino 
acids in the class B GPCR. Only the backbone of PAC1R is traced in 
green, for clarity. The residues of Gip1R (black, PDB code:2QKH), 
Glp1R (red, PDB code:3C5T), PAC1R (green, PDB code:3N94) and 
VIP2R (blue, PDB code:2X57) align remarkably well, depicting 
structural conservation, in spite of the absence of high sequential 
conservation in the family. 
 
The structure is further stabilized by an important interaction cluster formed 
by Asp59, Trp64, Val93, Arg95, Trp102 and Tyr109 (Figs. 4.11 and 4.12). Most of 
the residues in this cluster, Asp59, Trp64, Arg95, Trp102, are highly conserved. 
Residues Val93 and Tyr109 of this cluster are sequentially less conserved but still 
appear to make very important interactions. 




Figure 4.12. Stereo image of the electron density of the residues that 
form an important interaction cluster, which holds the core of the ECD 
together, in addition to the three disulphide bonds. Arg95 and Asp59 
make an important salt bridge, which is absent in most other ECD 
structures. 
 
Particularly, Tyr109 bends inward to contribute to hydrophobic interactions at 
the core through its aromatic ring while making a hydrogen bond with Asp59 through 
its hydroxyl group. Asp59, with its side chain bends towards the β-turn below helix 1, 
making important contacts with the backbone amides of Asn60, Ile61 and Thr62, to 
form a β-turn. Although the side chain of Asp59 bends towards the β-turn, it is still 
able to make a salt bridge with Arg95. This salt bridge is not observed in GIP1R and 
PTH1R. This is possible because the long side-chain of Arg95 is pushed down and 
towards Asp59 by the protruding side-chain of Met57. Furthermore, an interesting 
feature is that the peptidyl-prolyl bond at Phe106 is in the cis conformation. It 
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interacts with the backbone amide of Ser94, causing a turn at Pro107, just before the 
beginning of helix 2, thus, constraining its orientation further, in addition to the third 
disulphide bridge. 
The conserved residues overlap remarkably well in the structural alignment 
(Figs. 4.11 and 4.13), depicting their importance in holding the core domain together. 
The side chains of Arg95 (of PAC1R) and the corresponding lysine in VIP2R are 
positioned differently. Conformation of the conserved Asp(59) of VIP2R is slightly 
different when compared with other class B structures. This difference might be due 
to its interaction with a non VIP2R residue from an NCS partner rather than an 
inherent difference in the VIP2R structure. The different conformation of Arg95 in 
PAC1R brings it close to this conserved Asp, allowing the formation of a salt bridge 
between them which is absent in other structures. Formation of this salt bridge 
between residues from strands β1 and β4 provides additional stability to the core fold 
which is evident from the low B-factors in this region (Fig. 4.14). 
Superimposition of the PAC1R crystal structure with that of other class B 
GPCRs (Fig. 4.13) depicts that the sandwich fold is well conserved in this family, 
even though sequence alignment of the family members shows relatively less 
conservation (Fig. 4.1).  
 
 




Figure 4.13. Superimposition of the backbone of the ECD of class B 
members GIP1R (black, PDB code:2QKH), GLP1R (red, PDB 
code:3C5T), PAC1R (green, PDB code:3N94) and VIP2R (blue, PDB 
code:2X57). The disulphide bridges C34-C63, C54-C97 and C77-C113 
are labelled. 
 
In addition, the B-factor plot of PAC1R does not show any region of large 
conformational flexibility (Fig. 4.14). The B-factor for Cα residues throughout the 
ECD polypeptide is low, which is indicative of a stable conformation. High B-factors 




Figure 4.14 B-factor plot of PAC1R-ECD. The B-factors are indicated 
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4.4.3 Molecular determinants of PAC1R:PACAP interaction 
In accordance with the studies on the effects of N-terminal PACAP 
truncations on PAC1R binding and adenylate cyclase activation (Hou et al., 1994) and 
the two domain model of receptor activation (Hoare, 2005) the C-terminal domain of 
PACAP is sufficient to bind the receptor ECD. Furthermore, in the absence of 
experimental conformation of the binding of PACAP truncations to the isolated 
receptor ECD, Alphascreen assays with different PACAP truncations were performed 
to test a sufficient interaction region (Fig 4.7). Although, the three different peptides 
that were used had minor differences in receptor binding, they still showed adequate 
interaction. One of the peptides among these was chosen for alanine scan analysis to 
test for the molecular determinants of receptor binding. 
To determine the contribution of each amino acid for receptor interaction, 
every residue of PACAP (15-31) was mutated to alanine, one at a time. The residues 
that were alanine or glycine in the wild type peptide were left unchanged. The 
peptides having the mutated residue were used to compete with the wild type peptide 
for binding (Fig. 4.15). 
 
 
Figure 4.15. Alanine scan Alphascreen of PACAP (15-31). The bar 
with no peptide for competition gives the maximum signal. Addition of 
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the wild type peptide as competitor reduces the signal to almost zero. 
Some of the mutant peptides are unable to compete with the wild type 
peptide for binding to the receptor and are, therefore, unable reduce the 
Alphascreen signal. 
 
 The assay identified three Ala mutations that affect the binding to PAC1R the most. 
The K20A' mutation almost completely abolishes the ability of the peptide to bind the 
receptor ECD. The other important residues for binding are Lue27' and Val19'. This 
suggests that the major contribution to binding comes from a possible ionic 
interaction while other hydrophobic interactions might contribute to increase the 
binding capacity of the peptide. In the case of PTH1R and GIP1R also, the authors 
observe that the interaction of the receptor ECD and the corresponding peptide is 
mediated by positively charged residues on the peptide with further assistance from 
hydrophobic interactions. Due to the nature of the assay, in which high concentrations 
of the competing peptides are being used, there is a possibility that minor effects of 
the mutations will not be detected and only the large effects get detected. Therefore, 
although there is a possibility of getting false negatives in this assay, there is almost 
no possibility of obtaining a false positive signal. Lowering the concentration of the 
competing peptides would give signal for minor changes as well but would also 
simultaneously increase the possibility of false positives. Hence, in order to preferably 
avoid false positives, in lieu of false negatives, only high concentrations of the 
competing peptides were used. 
 
4.4.4  Peptide docking to receptor ECD 
Based on the results of the alanine scan, we tried to discern the mechanism of 
PACAP binding. AutoDock4.2 (Morris et al., 2009) offers a good means for searching 
all possible configurations and calculating the binding energy of the peptide and ECD. 
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To obtain a sterically and electrostatically plausible orientation of PACAP, we 
initially started with a blind search for the peptide binding site in our structure using 
the essential region (residues 8-27) of the PACAP structure (residues 1-38, PDBId: 
2D2P) in AutoDock 4.2. Guided by the putative peptide binding site, a solution of the 
blind search was chosen for further examination. The sidechains of the peptide 
residues at the interface with ECD were then made flexible and the search was 
repeated using a finer grid. The results were consistent with the hypothesis that 
PACAP 8-27 docks with PAC1R at the putative binding site, as observed in other 
ECD:hormone complex structures.  
 
Figure 4.16. Stereo view of the peptide:ECD interface. The PACAP 
peptide is represented in cyan while the ECD is represented in green. 
Important sidechains are labelled. The distance between E104 and 
K20' is 2.6 Å, indicating an ionic interaction between them.  
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The docking results correlate well with those of the Alphascreen assay. The 
PACAP residues that are identified to be important for binding, according to the 
assay, are oriented towards the ECD (Fig. 4.16). Val19' and Leu27' make hydrophobic 
interactions with the ECD. More importantly, Lys20' makes a salt bridge with Glu104 
of the ECD. This important interaction appears to explain the ability of the K20A' 
mutation to almost completely abrogate the peptide binding.  
 
(a)     (b) 
 
Figure 4.17. (a) Alphascreen assay of mutations in PAC1R affect the 
binding to PACAP. All the mutations were made on the outer surface 
of the receptor so that the structural core of PAC1R is unaffected. The 
mutants and the wildtype receptor ECDs were assayed for interaction 
with biotin-PACAP (6-38) at increasing equimolar concentration to 
enable the reading of the assay to reach saturation. (b) The location of 
the mutated residues on the surface of PAC1R ECD. ECD is coloured 
in green while the side chains of the mutated residues are shown as 
blue sticks. 
 
This interaction between the receptor and the peptide implies that mutating 
E104 should also affect PACAP binding in a reciprocal manner. Fig. 4.17 shows that 
the E104R mutation of the PAC1R ECD does reduce its binding to PACAP in an 
Alphascreen assay. In contrast, mutation in the surface hydrophobic residue (F84A) 
does not affect PACAP binding (Fig. 4.17). The point mutations are on the surface of 
the ECD and, therefore, are not expected to affect the fold of the protein. F84A acts as 
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a control to show that mutation of the residues that do not appear to make contacts 
with the receptor in the docking model do not affect peptide interaction in the assay. 
F110A affects PACAP binding, but to an extent much less than E104R. The side-
chain of F110 is oriented such that it forms the surface of the hydrophobic cluster, 
which has been implicated for ligand binding in other structures as well. Mutating 
F110 to alanine shows slight reduction in binding, thus, supporting its role in 
hydrophobic interactions with the peptide. Together, these data support the docking 
model of PACAP binding to the PAC1R ECD. 
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CHAPTER 5. DISCUSSION 
 
GPCRs have been implicated in a variety of cellular processes. As regulators 
of extracellular signal transduction their modulation can result in significant effects in 
cellular functions. Among the major classes of GPCRs, class B has proven to be the 
most structurally elusive, as no full length structure is yet available. The only 
available structures are those of partial domains of class B GPCRs. One of these 
domains, the N-terminal extracellular domain (ECD), has attracted significant interest 
as it is the site of hormone recognition. Attempts have been made to understand this 
process at the extracellular surface. In the absence of a structure of a full length 
receptor, structural studies on hormone recognition have been concentrated on the 
ECD. From the various studies on the PTH-calcitonin chimeras (Bergwitz et al., 
1996) and the receptors for glucagon and glucagon-like peptide (Runge et al., 2003, 
Runge et al., 2003), the role of ECD in ligand recognition has been well established. 
In addition, photo-affinity crosslinking studies on PTH (Gensure et al., 2003) and 
similar studies with CRFR1 (Assil-Kishawi and Abou-Samra, 2002) have displayed 
the role of juxtamembrane domains (J domain) in binding to the N-terminal region of 
the ligand. From all these studies, the ‘two-domain’ model of hormone binding has 
emerged. According to this model, the C-terminus of the ligand first interacts with the 
receptor ECD. This creates an ‘affinity trap’, which then allows the N-terminus of the 
ligand to interact with the J-domain (Fig. 5.1). Interaction with the J-domain activates 
the receptor and leads to downstream signalling. Molecular modelling has provided 
some insight into the possible interactions of PTH1 with the J-domain of its receptor 
(Monticelli et al., 2002). The NMR structure of the receptor bound form of PACAP 
shows a β-turn in the N-terminal region (Inooka et al., 2001). This prompts the fact 
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that the precise structural features of interactions at the J-domain might vary for 
different hormones, based on their sequence variation. Moreover, peptide hormones 
are thought to be unstructured in aqueous solution. Structural studies of isolated 
peptide hormones are impossible without the addition of either structure inducing 
polar solvents or the creation of membrane like environments using lipids. Molecular 
modelling has been employed using Class A structures to understand how peptides 
dock to the receptor (Ceraudo et al., 2008, Gensure et al., 2005). The previously 
reported ECD:hormone complex structures show a continuous α-helical structure in 
the C-terminal region of peptide. These studies suggest that peptide hormones adopt a 
mainly helical structure, only in the membrane environment or when binding to the 
ECD and remain largely unstructured in the extracellular matrix. The amphipathic 
nature of the peptide helices also supports this conjecture. In addition, N-terminal 
helix capping residues have also been suggested to facilitate receptor activation upon 
ligand docking (Neumann et al., 2008). Therefore, the mechanism of hormone 
binding to the receptor is considered to have contributions form hydrophobic burial of 
amphipathic helix its cooperative folding and helical propensity. Sequence variation 
among the peptides can provide a wide variation of these factors and is thought to 
contribute to the specificity and selectivity of ECD:hormone interaction. The precise 
mechanism, however, is further complicated by the possible oligomerization of 
receptors under native conditions. A Recent study explains the mechanism of GPCR 
dimerization which is disrupted upon ligand binding (Pioszak et al., 2010). 
Furthermore, some studies elucidate the mechanism of receptor activity modifying 
proteins (RAMPs) in hormone binding (ter Haar et al., 2010).  
However, the hormone recognition of PAC1R has remained controversial as a 
different binding mode has been suggested for it. In addition, a slight variation in the 
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otherwise conserved ECD fold has been suggested in the case of PAC1R (Sun et al., 
2007). The conflicting reports do not enable us to unite the mechanism of peptide 
binding and GPCR activation and, therefore, produce a gap in our understanding of 
class B GPCR biochemistry. Investigations on this discrepancy have been attempted 
in this thesis.  
The fold of PAC1R has been revealed by a crystal structure of the PAC1R 
ECD at 1.9 Å resolution. Even though the NMR structure of PAC1R has been 
highlighted to have certain unique features among this class of receptors, there have 
been some differing views (Parthier et al., 2009). The crystal structure of PAC1R 
ECD reveals the same overall fold as of other class B GPCR ECDs. In our X-ray 
crystallographic structure, PAC1R follows the conserved α+β fold as seen for other 
GPCRs of this class (Fig. 4.10). This fold is similar to the glucagon/VIP family due to 
the presence of a C-terminal helix. The previously reported NMR structure of PAC1R 
differs in the Cα tracing between β3 and β4 and a different topology of disulfide bond 
arrangement, as discussed in a review earlier (Parthier et al., 2009). While 
crystallographic structures enable us to observe only a snapshot of a dynamic protein 
structure, NMR structures have the ability to capture the dynamics in solution. 
However, the NMR structure of PAC1R is unlikely to be an alternate conformation in 
solution. Such an arrangement would be impossible without the disruption of the 
Cys77-Cys113 disulphide bond. The conformation of ~120 amino acid long ECDs is 
restrained by three conserved disulphide bonds. Of these, one disulphide linkage is 
between Cys77, in the Cα trace between β3 and β4, and Cys113 in α-helix 2. The 
presence of this disulphide bond restrains the conformation of the region between β3 
and β4, making local conformational flexibility extremely unlikely. Moreover, the Cα 
atoms in the β3 and β4 loop have been recognised to be very important for ligand 
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binding in other class B ECDs. In the complex structure of GIP1R, GLP1R (with both 
exendin-4 and glucagon) and PTH1R this loop forms a hydrophobic cluster. This 
hydrophobic cluster is the seat of hydrophobic interactions with the peptide in the 
complex structures of the above indicated ECDs. This cluster also contains the 
sequentially invariant Pro78, whose mutation in PTH1R leads to an embryonic lethal 
disorder. Therefore, the correct orientation of this loop is essential to structurally 
interpret PACAP binding. A different Cα trace in this region would change the 
hydrophobic pocket and would affect the binding of the peptide. In the NMR structure 
of PAC1R, PACAP makes no hydrophobic contacts in this region, making it unique 
in an otherwise unified class with respect to the hormone binding mechanism. 
Moreover, the polarity of PACAP in the NMR structure is opposite to all other known 
complex structures in this family. While the other structures report that the N-
terminus of the peptide is roughly oriented towards the N-terminus of the ECD, in the 
NMR-PAC1R structure, the PACAP is oriented in an opposite way (Fig. 2.5). 
 
 
Figure 5.1 Upon binding to ECD, the unstructured ligand (red) assumes 
a helical conformation. This creates an ‘affinity trap’ which allows the 
insertion of the peptide’s N-terminal region into the J-domain. This 
produces conformational changes in the transmembrane helices which 
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leads to the activation of the GPCR. The model has been made from the 
structure of transmembrane helices of opsin (PDB code: 3DQB) 
(Scheerer et al., 2008) and the ECD of GIP1R (PDB code: 2QKH) 
(Parthier et al., 2009). 
 
It has been proposed before that the N-terminal domain might also be able to 
act as an endogenous ligand (Dong et al., 2006). The mechanism suggested for it 
postulates that structural changes upon ligand binding might expose an intrinsic 
epitope corresponding to the tri-peptide Trp-Asp-Asn in the secretin receptor. Similar, 
mechanism has also been proposed for other members of the family having the 
corresponding Trp-Asp-Asn sequence. PAC1R also possesses this tri-peptide at 
position Trp58-Asp59-Asn60. From our structure it is very clear that Aps59 is tightly 
constrained with an intra-molecular salt bridge. On one side it forms a contact with 
the backbone amide of Thr62 while on the other side it forms a salt bridge with the 
terminal N of Arg95. Arg95 itself is very tightly constrained with both its side-chain 
N atoms, involving in forming contacts. The N atom, on the other side of Asp59, 
forms a hydrogen bond with the carboxyl group of the peptide bond between Ser103 
and Glu104. This constrains the arrangement in this region to a very tight 
conformation. It appears hard, from this structural point of view, that ligand binding 
could expose the endogenous epitope as the ΔG cost would be too high. Further 
experimental corroboration would be required to accept the endogenous epitope 
mechanism. 
Studying the properties and mechanisms of receptors are greatly simplified by 
the use of, preferably, non-peptide agonists/antagonists. Non-peptide antagonists are 
available for CRF1, CGRP, glucagon and GLP-1 receptors and have greatly aided in 
their study. Non-peptide antagonists can act by directly binding at the peptide binding 
site or allosterically by binding at a different site. In the case of CRFR1, the non-
peptide antagonist binds to the J-domain (Hoare et al., 2004). Antagonists can also 
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interact with RAMPs, as with CGRP and its inhibitor BIBN4096BS, to regulate 
receptor activation (Mallee et al., 2002). On the other hand, in GLP1R, with which 
PAC1R shares high sequence similarity, the antagonist T-0632 binds to the ECD and 
inhibits the binding of the peptide allosterically (Tibaduiza et al., 2001). The most 
important use of non-peptide antagonists is the ability to modify them for pathway 
specific inhibition. Such inhibitors promise the ability to provide deep insight into the 
pathway selectivity of receptor activation. The importance of the availability of high 
resolution structures cannot be over emphasized for the design and engineering of 
inhibitors with desired properties. 
 Based on our crystal structure and the docking results, we propose a model for 
the PACAP binding to PAC1R which complies with the two domain model. In this 
model, the PAC1R ECD adopts the same conserved fold as other class B GPCRs, and 
the PACAP peptide adopts as a single helix that docks into the similar peptide binding 
site as observed in GLP1 and PTH peptides. This model highlights several critical 
features that are supported by structures and biology of Class B GPCRs. First, PAC1R 
belongs to the same subfamily of receptors as glucagon and GLP1. Thus, it is 
expected that their ECDs adopt the same topology in their structures as confirmed by 
their crystal structures (Runge et al., 2008, Underwood et al., 2009). Second, PACAP 
also shares high degree sequence homology to glucagon and GLP1. Given this 
conservation and the conserved fold in their receptor ECD structures, it is reasonable 
to predict that PACAP adopts the same binding mode as GLP1 (Underwood et al., 
2009), thereby allowing its N-terminal residues to face the receptor TM domain to 
activate the receptor. Finally, the proposed model is consistent with the mutagenesis 
data, including the PACAP alanine scanning peptides and mutation in the PAC1R 
ECD, particularly the K20A' and E104R, respectively. These mutations stress a 
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charge complementary mechanism for the binding of PACAP to PAC1R. The same 
charge complementary mechanism has also been revealed for a number of Class B 
GPCRs, including PTH1R, GLP1R, and CRFR1. Together, the results from the 
structural, biochemical, and modelling studies highlight a consensus structural fold 
and mechanism of hormone recognition by Class B GPCRs, and should have 
important implications in hormone binding by several other members of Class B 























Assil-Kishawi, I. and Abou-Samra, A.B. (2002). Sauvagine Cross-links to the Second 
Extracellular Loop of the Corticotropin-releasing Factor Type 1 Receptor. 
Journal of Biological Chemistry, 277, 32558-32561. 
 
Bailey, S. (1994). The CCP4 suite- Programs for protein crystallogrpahy. Acta 
Crystallographica Section D-Biological Crystallography, 50, 760-763. 
 
Bergwitz, C., Gardella, T.J., Flannery, M.R., Potts, J.T., Kronenberg, H.M., Goldring, 
S.R. and Jüppner, H. (1996). Full Activation of Chimeric Receptors by 
Hybrids between Parathyroid Hormone and Calcitonin. Journal of Biological 
Chemistry, 271, 26469-26472. 
 
Brabet, P., Diriong, S., Journot, L., Bockaert, J. and Taviaux, S. (1996). Localization 
of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor 
(PACAP1-R) Gene to 7p15-p14 by Fluorescencein SituHybridization. 
Genomics, 38, 100-102. 
 
Buscail, L., Gourlet, P., Cauvin, A., De Neef, P., Gossen, D., Arimura, A., Miyata, A., 
Coy, D.H., Robberecht, P. and Christophe, J. (1990). Presence of highly 
selective receptors for PACAP (pituitary adenylate cyclase activating peptide) 
in membranes from the rat pancreatic acinar cell line AR 4-2J. Febs Letters, 
262, 77-81. 
 
Buscail, L., Gourlet, P., Cauvin, A., Deneef, P., Gossen, D., Arimura, A., Miyata, A., 
Coy, D.H., Robberecht, P. and Christophe, J. (1990). Presence of highly 
selective receptors for PACAP (Pituitary Adenylate-Cyclase Activating 
Peptide) in membranes from the Rat pancreatic acinar cell-line AR-4-2J. Febs 
Letters, 262, 77-81. 
 
Cauvin, A., Buscail, L., Gourlet, P., Deneef, P., Gossen, D., Arimura, A., Miyata, A., 
Coy, D.H., Robberecht, P. and Christophe, J. (1990). The novel VIP-like 
hupothalamic polypeptide PACAP interacts with high-affinity receptors in the 
human neuroblastoma cell-line NB-OK. Peptides, 11, 773-777. 
 
Cauvin, A., Robberecht, P., De Neef, P., Gourlet, P., Vandermeers, A., Vandermeers-
Piret, M.-C. and Christophe, J. (1991). Properties and distribution of receptors 
for pituitary adenylate cyclase activating peptide (PACAP) in rat brain and 
spinal cord. Regulatory Peptides, 35, 161-173. 
 
Ceraudo, E., Murail, S., Tan, Y.-V., Lacapere, J.-J., Neumann, J.-M., Couvineau, A. 
and Laburthe, M. (2008). The Vasoactive Intestinal Peptide (VIP) {alpha}-
Helix Up to C Terminus Interacts with the N-Terminal Ectodomain of the 
Human VIP/Pituitary Adenylate Cyclase-Activating Peptide 1 Receptor: 






Dautzenberg, Mevenkamp, Wille and Hauger (1999). N-Terminal Splice Variants of 
the Type I PACAP Receptor: Isolation, Characterization and Ligand 
Binding/Selectivity Determinants. Journal of Neuroendocrinology, 11, 941-
949. 
 
Dickson, L. and Finlayson, K. (2009). VPAC and PAC receptors: From ligands to 
function. Pharmacology & Therapeutics, 121, 294-316. 
 
Dong, M., Pinon, D.I., Asmann, Y.W. and Miller, L.J. (2006). Possible Endogenous 
Agonist Mechanism for the Activation of Secretin Family G Protein-Coupled 
Receptors. Molecular Pharmacology, 70, 206-213. 
 
Emsley, P., Lohkamp, B., Scott, W.G. and Cowtan, K. (2010). Features and 
development of Coot. Acta Crystallographica Section D-Biological 
Crystallography, 66, 486-501. 
 
Ewald, P. (1969). Introduction to the dynamical theory of X-ray diffraction. Acta 
Crystallographica Section A, 25, 103-108. 
 
Fredriksson, R., Lagerstrom, M.C., Lundin, L.G. and Schioth, H.B. (2003). The G-
protein-coupled receptors in the human genome form five main families. 
Phylogenetic analysis, paralogon groups, and fingerprints. Molecular 
Pharmacology, 63, 1256-1272. 
 
Gensure, R.C., Gardella, T.J. and Jüppner, H. (2005). Parathyroid hormone and 
parathyroid hormone-related peptide, and their receptors. Biochemical and 
Biophysical Research Communications, 328, 666-678. 
 
Gensure, R.C., Shimizu, N., Tsang, J. and Gardella, T.J. (2003). Identification of a 
Contact Site for Residue 19 of Parathyroid Hormone (PTH) and PTH-Related 
Protein Analogs in Transmembrane Domain Two of the Type 1 PTH 
Receptor. Mol Endocrinol, 17, 2647-2658. 
 
Gilman, A.G. (1987). G-PROTEINS - TRANSDUCERS OF RECEPTOR-
GENERATED SIGNALS. Annual Review of Biochemistry, 56, 615-649. 
 
Gottschall, P.E., Tatsuno, I., Miyata, A. and Arimura, A. (1990). Characterization and 
distribution of binding-sites for the hypothalamic peptide,Pituitary Adenylate 
Cyclase-Activating Polypeptide. Endocrinology, 127, 272-277. 
 
Gouet, P., Courcelle, E., Stuart, D.I. and M√©toz, F. (1999). ESPript: analysis of 
multiple sequence alignments in PostScript. Bioinformatics, 15, 305-308. 
 
Hahn, T., ed. International Tables for Crystallography Volume A: Space-group 
symmetry. 2006, International Union of Crystallography. 
 
Hashimoto, H., Nogi, H., Mori, K., Ohishi, H., Shigemoto, R., Yamamoto, K., 
Matsuda, T., Mizuno, N., Nagata, S. and Baba, A. (1996). Distribution of the 




rat brain: An in situ hybridization study. The Journal of Comparative 
Neurology, 371, 567-577. 
 
Hepler, J.R. and Gilman, A.G. (1992). G-PROTEINS. Trends in Biochemical 
Sciences, 17, 383-387. 
 
Hoare, S.R.J. (2005). Mechanisms of peptide and nonpeptide ligand binding to class 
B G-protein coupled receptors. Drug Discovery Today, 10, 417-427. 
 
Hoare, S.R.J., Sullivan, S.K., Schwarz, D.A., Ling, N., Vale, W.W., Crowe, P.D. and 
Grigoriadis, D.E. (2004). Ligand Affinity for Amino-Terminal and 
Juxtamembrane Domains of the Corticotropin Releasing Factor Type I 
Receptor:  Regulation by G-Protein and Nonpeptide Antagonists. 
Biochemistry, 43, 3996-4011. 
 
Holland, P.W.H., Garciafernandez, J., Williams, N.A. and Sidow, A. (1994). Gene 
duplications and the origins of vertebrate development. Development, 125-
133. 
 
Hou, X., Vandermeers, A., Gourlet, P., Vandermeers-Piret, M.C. and Robberecht, P. 
(1994). Structural requirements for the occupancy of rat brain PACAP 
receptors and adenylate cyclase activation. Neuropharmacology, 33, 1189-
1195. 
 
Howlin, B., Butler, S.A., Moss, D.S., Harris, G.W. and Driessen, H.P.C. (1993). 
TLSANL: TLS parameter-analysis program for segmented anisotropic 
refinement of macromolecular structures. Journal of Applied Crystallography, 
26, 622-624. 
 
Inooka, H., Ohtaki, T., Kitahara, O., Ikegami, T., Endo, S., Kitada, C., Ogi, K., Onda, 
H., Fujino, M. and Shirakawa, M. (2001). Conformation of a peptide ligand 
bound to its G-protein coupled receptor. Nat Struct Mol Biol, 8, 161-165. 
 
Ji, T.H., Grossmann, M. and Ji, I.H. (1998). G protein-coupled receptors I. Diversity 
of receptor-ligand interactions. Journal of Biological Chemistry, 273, 17299-
17302. 
 
Jones, M.B., Siderovski, D.R. and Hooks, S.B. (2004). The G beta gamma dimer as a 
novel source of selectivity in G-protein signaling: GGL-ing at convention. 
Molecular Interventions, 4, 200-214. 
 
Kleywegt, G. (1996). Use of Non-crystallographic Symmetry in Protein Structure 
Refinement. Acta Crystallographica Section D, 52, 842-857. 
 
Kleywegt, G.J. and Read, R.J. (1997). Not your average density. Structure, 5, 1557-
1569. 
 
Lam, H.C., Takahashi, K., Ghatei, M.A., Kanse, S.M., Polak, J.M. and Bloom, S.R. 




activating polypeptide in the rat brain and lung. European Journal of 
Biochemistry, 193, 725-729. 
 
Laskowski, R.A., Macarthur, M.W., Moss, D.S. and Thornton, J.M. (1993). 
PROCHECK - A program to check the sterechemical quality of protein 
structures. Journal of Applied Crystallography, 26, 283-291. 
 
Levitzki, A. (1986). BETA-ADRENERGIC RECEPTORS AND THEIR MODE OF 
COUPLING TO ADENYLATE-CYCLASE. Physiological Reviews, 66, 819-
854. 
 
Lutz, E.M., Ronaldson, E., Shaw, P., Johnson, M.S., Holland, P.J. and Mitchell, R. 
(2006). Characterization of novel splice variants of the PAC1 receptor in 
human neuroblastoma cells: Consequences for signaling by VIP and PACAP. 
Molecular and Cellular Neuroscience, 31, 193-209. 
 
Mallee, J.J., Salvatore, C.A., LeBourdelles, B., Oliver, K.R., Longmore, J., Koblan, 
K.S. and Kane, S.A. (2002). Receptor Activity-modifying Protein 1 
Determines the Species Selectivity of Non-peptide CGRP Receptor 
Antagonists. Journal of Biological Chemistry, 277, 14294-14298. 
 
Martin, J.-L., Feinstein, D.L., Yu, N., Sorg, O., Rossier, C. and Magistretti, P.J. 
(1992). VIP receptor subtypes in mouse cerebral cortex: evidence for a 
differnntial localization in astrocytes, microvessels and synaptosomal 
membranes. Brain Research, 587, 1-12. 
 
Masuo, Y., Ohtaki, T., Masuda, Y., Nagai, Y., Suno, M., Tsuda, M. and Fujino, M. 
(1991). Autoradiographic distribution of pituitary adenylate cyclase activating 
polypeptide (PACAP) binding sites in the rat brain. Neuroscience Letters, 126, 
103-106. 
 
Masuo, Y., Ohtaki, T., Masuda, Y., Tsuda, M. and Fujino, M. (1992). Binding sites 
for pituitary adenyloate cyclase activating polypeptide (PACAP): comparison 
with vasoactive intestinal polypeptide (VIP) binding site localization in rat 
brain sections. Brain Research, 575, 113-123. 
 
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C. and 
Read, R.J. (2007). Phaser crystallographic software. Journal of Applied 
Crystallography, 40, 658-674. 
 
Miyata, A., Arimura, A., Dahl, R.R., Minamino, N., Uehara, A., Jiang, L., Culler, 
M.D. and Coy, D.H. (1989). Isolation of a novel-38 residue-hypothalamic 
polypeptide which stimulates Adenylate-Cyclase in Pituitary-cells. 
Biochemical and Biophysical Research Communications, 164, 567-574. 
 
Möhler, H. and Fritschy, J.-M. (1999). GABAB receptors make it to the top - as 





Monticelli, L., Mammi, S. and Mierke, D.F. (2002). Molecular characterization of a 
ligand-tethered parathyroid hormone receptor. Biophysical Chemistry, 95, 
165-172. 
 
Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S. 
and Olson, A.J. (2009). AutoDock4 and AutoDockTools4: Automated docking 
with selective receptor flexibility. Journal of Computational Chemistry, 30, 
2785-2791. 
 
Murshudov, G.N., Vagin, A.A. and Dodson, E.J. (1997). Refinement of 
macromolecular structures by the maximum-likelihood method. Acta 
Crystallographica Section D-Biological Crystallography, 53, 240-255. 
 
Neumann, J.-M., Couvineau, A., Murail, S., Lacapère, J.-J., Jamin, N. and Laburthe, 
M. (2008). Class-B GPCR activation: is ligand helix-capping the key? Trends 
in Biochemical Sciences, 33, 314-319. 
 
Nomura, M., Ueta, Y., Serino, R., Kabashima, N., Shibuya, I. and Yamashita, H. 
(1996). PACAP type I receptor gene expression in the paraventricular and 
supraoptic nuclei of rats. NeuroReport, 8, 67-70. 
 
Ohno, S., ed. Evolution by gene duplication. 1970, Springer-Verlag: New York. 
 
Ohtaki, T., Watanabe, T., Ishibashi, Y., Kitada, C., Tsuda, M., Gottschall, P.E., 
Arimura, A. and Fujino, M. (1990). Molecular identification of receptor for 
pituitary adenylate cyclase activating polypeptide. Biochemical and 
Biophysical Research Communications, 171, 838-844. 
 
Otto, C., Zuschratter, W., Gass, P. and Schütz, G. (1999). Presynaptic localization of 
the PACAP-typeI-receptor in hippocampal and cerebellar mossy fibres. 
Molecular Brain Research, 66, 163-174. 
 
Otwinowski, Z. and Minor, W., Processing of X-ray diffraction data collected in 
oscillation mode, in Macromolecular Crystallography, Pt A. 1997. p. 307-326. 
 
Padilla, J.E. and Yeates, T.O. (2003). A statistic for local intensity differences: 
robustness to anisotropy and pseudo-centering and utility for detecting 
twinning. Acta Crystallographica Section D, 59, 1124-1130. 
 
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le 
Trong, I., Teller, D.C., Okada, T., Stenkamp, R.E., Yamamoto, M. and 
Miyano, M. (2000). Crystal structure of rhodopsin: A G protein-coupled 
receptor. Science, 289, 739-745. 
 
Pannu, N.S. and Read, R.J. (1996). Improved Structure Refinement Through 
Maximum Likelihood. Acta Crystallographica Section A, 52, 659-668. 
 
Parthier, C., Kleinschmidt, M., Neumann, P., Rudolph, R., Manhart, S., Schlenzig, D., 
Fanghanel, J., Rahfeld, J.U., Demuth, H.U. and Stubbs, M.T. (2007). Crystal 




receptor. Proceedings of the National Academy of Sciences of the United 
States of America, 104, 13942-13947. 
 
Parthier, C., Reedtz-Runge, S., Rudolph, R. and Stubbs, M.T. (2009). Passing the 
baton in class B GPCRs: peptide hormone activation via helix induction? 
Trends Biochem Sci, 34, 303-10. 
 
Patterson, A.L. (1934). A Fourier Series Method for the Determination of the 
Components of Interatomic Distances in Crystals. Physical Review, 46, 372. 
 
PebayPeyroula, E., Rummel, G., Rosenbusch, J.P. and Landau, E.M. (1997). X-ray 
structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in 
lipidic cubic phases. Science, 277, 1676-1681. 
 
Pioszak, A.A., Harikumar, K.G., Parker, N.R., Miller, L.J. and Xu, H.E. (2010). 
Dimeric Arrangement of the Parathyroid Hormone Receptor and a Structural 
Mechanism for Ligand-induced Dissociation. Journal of Biological Chemistry, 
285, 12435-12444. 
 
Pioszak, A.A., Parker, N.R., Suino-Powell, K. and Xu, H.E. (2008). Molecular 
Recognition of Corticotropin-releasing Factor by Its G-protein-coupled 
Receptor CRFR1. Journal of Biological Chemistry, 283, 32900-32912. 
 
Pioszak, A.A. and Xu, H.E. (2008). Molecular recognition of parathyroid hormone by 
its G protein-coupled receptor. Proceedings of the National Academy of 
Sciences, 105, 5034-5039. 
 
Pisegna, J.R. and Wank, S.A. (1993). Molecular cloning and functional expression of 
the pituitary adenylate cyclase-activating polypeptide type I receptor. 
Proceedings of the National Academy of Sciences of the United States of 
America, 90, 6345-6349. 
 
Potterton, E., Briggs, P., Turkenburg, M. and Dodson, E. (2003). A graphical user 
interface to the CCP4 program suite. Acta Crystallographica Section D-
Biological Crystallography, 59, 1131-1137. 
 
Rice, L.M. and BrüNger, A.T. (1994). Torsion angle dynamics: Reduced variable 
conformational sampling enhances crystallographic structure refinement. 
Proteins: Structure, Function, and Bioinformatics, 19, 277-290. 
 
Rodbell, M., Birnbaum.L, Pohl, S.L. and Krans, H.M.J. (1971). GLUCAGON-
SENSITIVE ADENYL CYCLASE SYSTEM IN PLASMA MEMBRANES 
OF RAT LIVER .5. OBLIGATORY ROLE OF GUANYL NUCLEOTIDES 
IN GLUCAGON ACTION. Journal of Biological Chemistry, 246, 1877-&. 
 
Rodríguez-Henche, N., Jamen, F., Leroy, C., Bockaert, J. and Brabet, P. (2002). 
Transcription of the mouse PAC1 receptor gene: cell-specific expression and 
regulation by Zac1. Biochimica et Biophysica Acta (BBA) - Gene Structure 





Ross, E.M. and Gilman, A.G. (1977). RESOLUTION OF SOME COMPONENTS 
OF ADENYLATE-CYCLASE NECESSARY FOR CATALYTIC 
ACTIVITY. Journal of Biological Chemistry, 252, 6966-6969. 
 
Rossmann, M.G. and Blow, D.M. (1962). The detection of sub-units within the 
crystallographic asymmetric unit. Acta Crystallographica, 15, 24-31. 
 
Runge, S., Gram, C., Bräuner-Osborne, H., Madsen, K., Knudsen, L.B. and Wulff, 
B.S. (2003). Three Distinct Epitopes on the Extracellular Face of the Glucagon 
Receptor Determine Specificity for the Glucagon Amino Terminus. Journal of 
Biological Chemistry, 278, 28005-28010. 
 
Runge, S., Thøgersen, H., Madsen, K., Lau, J. and Rudolph, R. (2008). Crystal 
Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular 
Domain. Journal of Biological Chemistry, 283, 11340-11347. 
 
Runge, S., Wulff, B.S., Madsen, K., Bräuner-Osborne, H. and Knudsen, L.B. (2003). 
Different domains of the glucagon and glucagon-like peptide-1 receptors 
provide the critical determinants of ligand selectivity. British Journal of 
Pharmacology, 138, 787-794. 
 
Rupp, B. (2009). Biomolecular Crystallography: Principles, Practice, and 
Application to Structural Biology, Garland Science, New York. 
 
Scheerer, P., Park, J.H., Hildebrand, P.W., Kim, Y.J., Krauß, N., Choe, H.-W., 
Hofmann, K.P. and Ernst, O.P. (2008). Crystal structure of opsin in its G-
protein-interacting conformation. Nature, 455, 497-502. 
 
Scheerer, P., Park, J.H., Hildebrand, P.W., Kim, Y.J., Krausz, N., Choe, H.-W., 
Hofmann, K.P. and Ernst, O.P. (2008). Crystal structure of opsin in its G-
protein-interacting conformation. Nature, 455, 497-502. 
 
Sherwood, N.M., Krueckl, S.L. and McRory, J.E. (2000). The origin and function of 
the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon 
superfamily. Endocr. Rev., 21, 619-670. 
 
Shioda, S., Shuto, Y., Somogyvári-Vigh, A., Legradi, G., Onda, H., Coy, D.H., 
Nakajo, S. and Arimura, A. (1997). Localization and gene expression of the 
receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. 
Neuroscience Research, 28, 345-354. 
 
Spongier, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburgt, P.H. and 
Journot, L. (1993). Differential signal transduction by five splice variants of 
the PACAP receptor. Nature, 365, 170-175. 
 
Suda, K., Smith, D.M., Ghatei, M.A. and Bloom, S.R. (1992). Investigation of the 
interaction of VIP binding sites with VIP and PACAP in human brain. 





Suda, K., Smith, D.M., Ghatei, M.A., Murphy, J.K. and Bloom, S.R. (1991). 
Investigation and characterization of receptors for pituitary adenylate cyclase-
activating polypeptide in human brain by radioligand binding and chemical 
cross-linking. Journal Name: Journal of Clinical Endocrinology and 
Metabolism; (USA); Journal Volume: 72:5, Medium: X; Size: Pages: 958-964. 
 
Sun, C., Song, D., Davis-Taber, R.A., Barrett, L.W., Scott, V.E., Richardson, P.L., 
Pereda-Lopez, A., Uchic, M.E., Solomon, L.R., Lake, M.R., Walter, K.A., 
Hajduk, P.J. and Olejniczak, E.T. (2007). Solution structure and mutational 
analysis of pituitary adenylate cyclase-activating polypeptide binding to the 
extracellular domain of PAC1-RS. Proceedings of the National Academy of 
Sciences, 104, 7875-7880. 
 
Tatsuno, I., Gottschall, P.E., Köves, K. and Arimura, A. (1990). Demonstration of 
specific binding sites for pituitary adenylate cyclase activating polypeptide 
(PACAP) in rat astrocytes. Biochemical and Biophysical Research 
Communications, 168, 1027-1033. 
 
ter Haar, E., Koth, C.M., Abdul-Manan, N., Swenson, L., Coll, J.T., Lippke, J.A., 
Lepre, C.A., Garcia-Guzman, M. and Moore, J.M. (2010). Crystal Structure of 
the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals 
the Site of Drug Antagonism. Structure (London, England : 1993), 18, 1083-
1093. 
 
Tesmer, J.J.G. (2010). The quest to understand heterotrimeric G protein signaling. 
Nature Structural & Molecular Biology, 17, 650-652. 
 
Tesmer, J.J.G., Sunahara, R.K., Gilman, A.G. and Sprang, S.R. (1997). Crystal 
structure of the catalytic domains of adenylyl cyclase in a complex with G(s 
alpha).GTP gamma S. Science, 278, 1907-1916. 
 
Tibaduiza, E.C., Chen, C. and Beinborn, M. (2001). A small molecule ligand of the 
glucagon-like peptide 1 receptor targets its amino-terminal hormone binding 
domain. J Biol Chem, 276, 37787-93. 
 
Tibaduiza, E.C., Chen, C. and Beinborn, M. (2001). A small molecule ligand of the 
glucagon-like peptide 1 receptor targets its amino-terminal hormone binding 
domain. Journal of Biological Chemistry, 276, 37787-37793. 
 
Underwood, C.R., Garibay, P., Knudsen, L.B., Hastrup, S., Peters, G.H., Rudolph, R. 
and Reedtz-Runge, S. (2009). Crystal Structure of Glucagon-like Peptide-1 in 
Complex with the Extracellular Domain of the Glucagon-like Peptide-1 
Receptor. Journal of Biological Chemistry, 285, 723-730. 
 
Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., 
Fournier, A., Chow, B., Hashimoto, H., Galas, L. and Vaudry, H. (2009). 
Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years 





Winn, M.D., Isupov, M.N. and Murshudov, G.N. (2001). Use of TLS parameters to 
model anisotropic displacements in macromolecular refinement. Acta 
Crystallographica Section D, 57, 122-133. 
 
Zawilska, J.B., Niewiadomski, P. and Nowak, J.Z. (2003). PAC1 receptors in chick 
cerebral cortex: characterization by binding of pituitary adenylate cyclase-
activating polypeptide, [125I]-PACAP27. Neuroscience Letters, 338, 155-158. 
 
 
 
 
